It is made available under a CC-BY-NC 4.0 International license .

1	Kir2.1 mutations differentially increase the risk of flecainide proarrhythmia in
2	Andersen Tawil Syndrome
3	
4	Francisco M. Cruz, PhD ^{1,*} , Ana I. Moreno-Manuel, MSc ¹ , Patricia Sánchez Pérez, PhD ¹ ,
5	Juan Manuel Ruiz-Robles, MSc', Paula García Socuellamos, PhD', Lilian K. Gutiérrez,
6	MSc', María Linarejos Vera-Pedrosa, MSc', Amaia Talavera Gutierrez, PhD', Gema
7	Mondéjar Parreño, PhD', Alvaro Macías, PhD', Isabel Martínez-Carrascoso, MSc',
8	Francisco J Bermúdez-Jiménez, MD, PhD ^{1,4,5} , Salvador Arias Santiago, MD, PhD, ³
9	Fernando Martínez de Benito, PhD ^{1/2} , Aitana Braza-Boils, PhD ^{2/3} , Carmen Valenzuela,
10	PhD ^o , CA Morillo, MD ^{1,10} , Esther Zorio, MD, PhD ^{2,01,0} , Juan Jimenez-Jaimez, MD ^{1,0} , Jose
11	Jalife, MD, PhD
12	10 periode National Contro for Condinues and Passarah (CNIIC) Madrid. Opein
13	Spanish National Centre for Cardiovascular Research (CNIC), Madrid, Spain.
14	Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV),
15	Mauriu, Spain. ³ Deportmente of Medicine and Melecular and Integrative Developmy, University of
10	Michigon Ann Arbor MI USA
17	Michigan, Ann Albor, Mi, USA. ⁴ Cardiology Sarvice, Virgen de les Nieves University Hespital, Cronada, Spain
10	⁵ Institute of Piesenitery Research of Crenede (IRS), Spain.
19	⁶ CAEAMUCME Descente Creur, Institute de Investigenién Conitarie Le Fe. Velencie
20	CAFAMUSME Research Group, Instituto de Investigación Sanitaria La Fe, Valencia,
$\frac{21}{22}$	Spaill. ⁷ Inherited Cardian Diagona Unit University and Delytophnic Heapitel La Eq. Valencia
22	Innenteu Cardiac Disease Onit, Oniversity and Polytechnic Hospital La Fe, Valencia,
23	Spain. ⁸ Madicina Department, University of Valencia, Spain
24 25	⁹ Piemedical Pessearch Institute Sele Merreele (IIPM), Medrid, Spein
25	¹⁰ Department of Cardiao Sciences, Libin CVI, University of Calgory, Canada
20	Department of Cardiac Sciences, Libin CVI, Oniversity of Cargary, Canada.
21	Shart Title: ATS1 mutations and flooginide prearrhythmic
20	Short The. ATST mutations and necamide proatmythina
29	*Corresponding outbors:
21	Losé Jolife MD PbD
31	Cardiae Arrhythmia Laboratory
32	Contro Nacional do Investigacionas Cardiovascularos (CNIC)
33	Melcher Eernández Almagre 2, 28020 Madrid, Spain
35	Email: ijalife@cnic.es
36	Telephone: ± 34.01 453 12 00 (Evt. 1512)
30	EAV: 124 01 452 12 65
38	T AA. +54-51 455 12 05
30	Francisco Miquel Cruz PhD
40	Cardiac Arrhythmia Laboratory
40	Centro Nacional de Investigaciones Cardiovasculares (CNIC)
$\frac{1}{42}$	Melchor Fernández Almagro 3, 28029 Madrid, Spain
43	Email: fmcruz@cnic.es
43 ΛΛ	Telephone: ± 34.01 453 12 00
44 15	FΔY· ±34-01 453 12 65
ч <i>э</i> 46	
40 Δ7	Keywords: Ion channel diseases Kir2 1-Nav1 5 channelosome ATS1 class-lo AADs
	Flecainide Arrhythmias Sudden Cardiac Death
49 49	
50	
51	
52	
	Total words a work

53 Total word count:

It is made available under a CC-BY-NC 4.0 International license .

54 Abstract

55 Background:

Flecainide and other class-Ic antiarrhythmic drugs (AADs) are widely used in Andersen-Tawil syndrome type 1 (ATS1) patients. However, class-Ic drugs might be proarrhythmic in some cases. We investigated the molecular mechanisms of class-I AADs proarrhythmia and whether they might increase the risk of death in ATS1 patients with structurally normal hearts.

61

62 Methods and Results: Of 53 ATS1 patients reviewed from the literature, 54% responded 63 partially to flecainide, with ventricular arrhythmia (VA) reduction in only 23%. Of the latter 64 patients, VA persisted in 20-50%. Flecainide was ineffective in 23%, and surprisingly, 13.5% suffered a non-fatal cardiac arrest. In five cardiac-specific ATS1 mouse models (Kir2.1^{Δ314-315}, Kir2.1^{C122Y}, Kir2.1^{G215D} and Kir2.1^{R67W} and Kir2.1^{S136F}), flecainide or 65 66 propafenone (40 mg/Kg i.p.) differentially prolonged the P wave, and the PR, QRS and 67 QTc intervals compared to Kir2.1^{WT}; Kir2.1^{S136F} had milder effects. Flecainide increased VA inducibility in all mutant mice except Kir2.1^{S136F}, which exhibited significant VA reduction. At baseline, Kir2.1^{G215D} cardiomyocytes had the lowest inward rectifier K+ channel (I_{K1}) reduction, followed by Kir2.1^{C122Y}, Kir2.1^{R67W} and Kir2.1^{S136F}. Kir2.1^{C122Y} 68 69 70 71 cardiomyocytes had a significant decrease in sodium inward current (I_{Na}). Flecainide (10 72 μ M) slightly increased I_{k1} density in Kir2.1^{WT} and Kir2.1^{S136F}, while it decreased both I_{k1} and I_{Na} in Kir2.1^{C122Y} and Kir2.1^{R67W}, despite normal trafficking of mutant channels. Optical 73 74 mapping in ATS1 patient-specific iPSC-CM monolayers expressing Kir2.1^{C122Y}, Kir2.1^{G215D} 75 and Kir2.1^{R67W} showed an increase in rotor incidence at baseline and under flecainide, 76 77 confirming the drug's proarrhythmic effect. Lastly, in-silico molecular docking predicts that the Kir2.1-Cys₃₁₁ pharmacophore-binding site is altered in Kir2.1^{C122Y} heterotetramers, 78 79 reducing flecainide accessibility and leading to channel closure and arrhythmias.

80

81 **Conclusions**: Class-Ic AADs are only partially effective and might be proarrhythmic in 82 some ATS1 patients. Kir2.1 mutations impacting the resting membrane potential and 83 cellular excitability create a substrate for life-threatening arrhythmias, raising significant 84

84 concern about using these drugs in some ATS1 patients.

85 CLINICAL PERSPECTIVE

86 NOVELTY AND SIGNIFICANCE87

88 What is known?

- Andersen-Tawil syndrome type 1 (ATS1) is a rare autosomal dominant disease
 caused by loss-of-function mutations in the *KCNJ2* gene, which encodes the Kir2.1
 channel responsible for the repolarizing, strong inwardly rectifying current I_{K1}.
- ATS1 treatment is empirical and subject to clinical judgment. It includes the use of class-Ic antiarrhythmic drugs (AADs), mainly flecainide, alone or in combination with β-adrenergic blocking drugs. However, pharmacological treatment is partial and might fail, leading to life-threatening ventricular arrhythmias (VA) and sudden cardiac death (SCD) in some ATS1 patients.
- Some ATS1 mutations are known to disrupt the Kir2.1-Nav1.5 channelosome in mice and human iPSC-CMs, with consequent reductions in cardiac excitability and conduction velocity (CV), leading to VA, which may be exacerbated by flecainide.

100 What new information does this article contribute?

- In our analysis of 53 ATS1 patients, flecainide showed partial effectiveness. While
 a few patients experienced complete disappearance of VA, others had persistent
 arrhythmias and even suffered non-fatal cardiac arrest while on medication.
- In murine models expressing five relevant ATS1 mutations, flecainide or propafenone produced differential alteration in the P wave, PR, QRS and QTc intervals, and increased VA inducibility compared with Kir2.1^{WT} mice. Additionally, flecainide differentially affected I_{K1} and the Na⁺ inward current (I_{Na}) current densities despite normal trafficking of mutant channels.
- In patient-specific induced pluripotent stem cell derived cardiomyocyte (iPSC-CM)
 monolayers flecainide reduced CV and increased rotor incidence, confirming the
 drugs´ proarrhythmic effect.
- *In-silico* molecular docking studies predicted that the Cys₃₁₁ pharmacophore
 binding site and flecainide accessibility are altered in mutated Kir2.1 channels,
 leading to premature channel closure and arrhythmias.
- We conclude that class-lc AADs are only partially effective and might be proarrhythmic in some ATS1 patients.
- These findings raise concern about the use of class-Ic AADs in ATS1 patients and highlight the need for further studies to guide personalized therapy.

119 Non-standard Abbreviation and Acronyms

- 120 AAD Antiarrhythmic drug
- 121 AP Action potential
- 122 APD Action potential duration
- 123 ATS1 Andersen-Tawil Syndrome Type 1
- 124 BiVT Bidirectional ventricular tachycardia
- 125 CV Conduction velocity
- 126 ECG Electrocardiogram
- 127 hiPSC-CMs Induced pluripotent stem cell-derived cardiomyocytes
- 128 IC Isogenic control
- 129 ICD Implantable cardiac defibrillator
- 130 i.p. Intraperitoneal
- 131 i.v. Intravenously
- 132 NSVT Nonsustained ventricular tachycardia
- 133PIP2Phosphatidylinositol-4, 5-bisphosphate
- 134 PVC Premature ventricular contraction
- 135 PVT Polymorphic ventricular tachycardia
- 136 RMP Resting membrane potential
- 137 SASA Solvent Accessible
- 138 SCD Sudden cardiac death
- 139 SNRT Sinus node recovery time
- 140 TdP Torsades de pointe
- 141 VA Ventricular arrhythmias
- 142 VE Ventricular extrasystoles
- 143 VT Ventricular tachycardia
- 144 WT Wild type

It is made available under a CC-BY-NC 4.0 International license .

145 Introduction

146 Andersen-Tawil syndrome type 1 (ATS1) is a rare autosomal dominant disease 147 caused by loss-of-function mutations in the KCNJ2 gene, which codes the strong inward 148 rectifier potassium channel Kir2.1 responsible for the repolarizing current I_{K1}^{1} I_{K1} plays a 149 vital role maintaining the resting membrane potential (RMP) and the final phase of action 150 potential (AP) repolarization. Thus, loss-of-function mutations in KCNJ2 substantially decrease I_{K1} , with consequent prolongation of the AP duration (APD) and corrected QT 151 (QTc) interval.² These events predispose ATS1 patients to a triad of symptoms including 152 153 periodic paralysis, dysmorphias, and cardiac electrical alterations that may lead to high-154 burden polymorphic ventricular extrasystoles, biventricular tachycardia (BiVT), and 155 sudden cardiac death (SCD)³ by mutation-dependent mechanisms that are far from being 156 fully understood. Accordingly, it is unknown why life-threatening arrhythmias occur in 157 these patients, why some mutations have a more severe phenotype than others, even 158 within the same family, and how to treat each individual patient. Currently ATS1 treatment is empirical and subject to clinical judgment.⁴ Medical devices like implantable cardiac 159 160 defibrillators (ICDs) are frequently indispensable in the management of severe and 161 symptomatic cardiac arrhythmias. However, ICDs may induce inappropriate shocks and patients are not exempt from SCD risk.4-6 Pharmacological treatment includes class-lc 162 antiarrhythmic drugs (AADs), mainly flecainide or propafenone alone or in combination 163 with β -adrenergic blocking drugs.^{7,8} However, class-Ic drugs may fail or are proarrhythmic 164 in ATS1 patients⁴ due to poorly understood mechanisms. 165

166 More than 90 ATS1-associated loss-of-function mutations have been identified and 167 distributed throughout the Kir2.1 protein structure. Mutations may affect channel trafficking, channel gating, or ion selectivity properties through molecular mechanisms that 168 are incompletely understood.⁹ Additionally, Kir2.1 forms channelosomes with Nav1.5 169 proteins, responsible for the sodium inward current (I_{Na}) .¹⁰⁻¹² This specialized molecular 170 171 complex plays a crucial role in maintaining cardiac excitability and rhythm by stabilizing 172 the RMP and initiating the AP, ensuring coordinated cardiac activity. We have previously 173 shown that, in addition to sequestering the Kir2.1 protein in the Golgi apparatus,¹³ the Kir2.1^{Δ 314-315} mutation also prevents Na_v1.5 membrane trafficking, thus altering the 174 function of both proteins *in-vitro* and *in-vivo*.²⁰ More recently, we demonstrated that, while maintaining trafficking ability, the extracellular Kir2.1^{C122Y} mutation that disrupts 175 176 177 interactions of the channel with phosphatidyl inositol 4.5-bisphosphate (PIP₂) also 178 produces temporal instability of both Kir2.1 and Nav1.5 proteins and reduces excitability 179 *in-vivo.*¹⁴ Thus, the above results underscore the complexity of the mechanisms governing 180 Kir2.1-Nav1.5 channelosome function, and it is clear that each ATS1 mutation exhibits 181 distinct molecular mechanisms despite targeting the same gene. To date, only a handful 182 of studies have addressed the potential alterations in the surrounding molecular context 183 that governs cardiac activity, including Nav1.5 channels. There is, therefore, a significant 184 discrepancy between what is known and what should be known regarding molecular 185 mechanisms for a more effective treatment of each specific mutation leading to ATS1^{15,16}. 186 The lack of mechanistic knowledge significantly hinders our understanding of the cardiac 187 arrhythmia phenotype and prevents progress in disease treatment and SCD prevention. 188 No studies have been conducted to date to determine the impact of flecainide or any other 189 class-lc AADs on the electrical activity of the Kir2.1-Nav1.5 channelosome, which could 190 vary significantly depending on the specific ATS1 mutation.

191 In this article, we review available clinical data and demonstrate that the cardiac 192 electrical response of ATS1 patients to class-Ic AADs is highly variable, and at times 193 contrary to anticipated. While some patients benefit from the use of these drugs, others do 194 not, and yet others may get worse. We hypothesize that the ultimate effect of class-lc 195 AADs in a given ATS1 patient will depend on the precise electrophysiological 196 consequences of the Kir2.1 loss-of-function mutation. Specifically, we surmise that mutations impacting both RMP (I_{K1} reduction) and cellular excitability by altering Na_V1.5 197 198 function (I_{Na} reduction) and channel availability (through RMP-mediated depolarization),

It is made available under a CC-BY-NC 4.0 International license .

- 199 may potentially create a substrate for life-threatening arrhythmias, particularly promoted
- 200 by class-lc AADs treatment. Our approach is multidisciplinary, and our results emphasize
- 201 the need to elucidate the pathophysiology of arrhythmias in individual patients with ATS1,
- and identify an effective, more personalized therapy that reduces proarrhythmia risk.

203 Materials & Methods

204The authors declare that all supporting data are available within the article. Please205see the Major Resources Table and Supplemental Methods for more details.

206

207 Ethics Statement. All animal experimental procedures conformed to EU Directive 208 2010/63EU and Recommendation 2007/526/EC. We obtained skin biopsies from patients carrying the Kir2.1^{C122Y}, Kir2.1^{G215D} and Kir2.1^{R67W} mutation after written informed consent, 209 210 previously approved by local institutional review (2020-411-1, 2020-582-1), according to 211 the Ethics Committee for Research of CNIC and the Carlos III Institute (CEI PI58 2019-212 v3), Madrid, Spain. The local ethics committees and the Animal Protection Area of the 213 Comunidad Autónoma de Madrid (PROEX 111.4/20 and 226.5/23) approved the animal 214 protocols.

215

216 Mice. We obtained 4-5-weeks-old C57BL/6J male mice from the Charles River 217 Laboratories. Animals were reared and housed according to CNIC animal facility 218 guidelines and regulations.

219

220 AAV vector production, purification, and mouse model generation. AAV vectors were 221 generated using the cardiomyocyte-specific troponinT proximal promoter (cTnT) and encoding wildtype Kir2.1 (Kir2.1^{WT}) or the ATS1 mutant channels (Kir2.1 $^{\Delta 314-315}$, Kir2.1^{C122Y}, Kir2.1^{G215D} and Kir2.1^{R67W} and Kir2.1^{S136F}), followed by tdTomato report. 222 223 224 Vectors were packaged into AAV serotype 9 (AVV9) and produced by the triple 225 transfection method, using HEK293T cells as described previously.^{17,18} Mice were 226 anesthetized with ketamine (60 mg/kg) and xylazine (20 mg/kg) by intraperitoneal (i.p.) route. Thereafter, mice were inoculated with 3.5^x10¹⁰ viral particles through the femoral 227 228 vein at a final volume of 50µL. Only well-inoculated animals were included in the studies. 229 All experiments were performed 8-to-10 weeks after infection. Ex-vivo fluorescent signal 230 confirming cardiac expression and distribution of protein expression was assessed as 231 described.¹⁹

232

233 Drugs. Flecainide-acetate (10mg/ml injection solution; Mylan pharmaceuticals) and 234 propafenone-hydrochloride (Sigma) were dissolved and administered i.p. in mice at a single dose of 40 mg/kg.²⁰ Fresh drug solutions were prepared for each experiment and 235 236 further dilutions were carried out in external solution to obtain the desired final 237 concentration for patch clamping and optical mapping experiments. Control solutions 238 always contained the same solvent concentrations as the test solution. ECGs were 239 recorded for 1 min at baseline and an additional 5 min after intraperitoneal injection of 240 flecainide or propafenone. hiPSCs-CM monolayers were incubated in the presence of 1 µM flecainide and isolated mouse cardiomyocytes expressing Kir2.1^{WT}, Kir2.1^{C122Y}, 241 Kir2.1^{R67W}, Kir2.1^{G215D}, Kir2.1^{R67W} and Kir2.1^{S136F} channels were recorded at baseline and 242 243 after 10 min of incubation with a final concentration of 10 µM of flecainide (IC₅₀ for Nav1.5 244 channels).²¹

245

Surface ECG recording. Mice were anesthetized using isoflurane inhalation (0.8-1.0% volume in oxygen) and maintained at 37°C on a heating plate. Four-lead surface ECGs were recorded for 6 min (1 min baseline + 5 min after i.p. drug) using subcutaneous limb electrodes connected to an MP36R amplifier unit (BIOPAC Systems). Data acquisition and analyses were performed using AcqKnowledge software.

251

In-vivo intracardiac recording, stimulation, and drug administration. An octopolar catheter (Science) was inserted through the jugular vein and advanced into the right ventricle as previously described.²² VA inducibility was assessed by applying consecutive trains at 10Hz and 25Hz, respectively.

256

257 Cardiomyocyte isolation. The procedure was performed as previously described.²³ (See
 258 Supplemental Methods).

259

Patch-clamping in isolated cardiomyocytes. The whole-cell patch-clamp technique as
 well as data analysis procedures and internal and external solutions (*Supplementary Table 1*) were similar to those previously described.^{9–13} Details are presented in the
 Supplemental Methods.

264

265 Generation, culture, and differentiation of iPSC-CMs. We reprogrammed primary 266 fibroblasts derived from skin biopsies from ATS1 patients (C122Y, R67W and G215D) to 267 iPSCs using the Sendai virus for transfection of Yamanaka's factors: OCT4, KLF4, c-Myc, and SOX2, as previously described.²⁴ HiPSCs were differentiated into hiPSC-CMs using 268 small molecules-mediated canonical Wnt pathway modulation as previously described.^{25,26} 269 270 HiPSC-CMs were purified from non-myocytes following the MACS negative selection 271 protocol (Miltenyi Biotec Kit) and seeded for 7 days on a PDMS substrate to improve 272 cardiomyocyte maturation. See Supplemental Methods for details.

273

Optical Mapping in iPSC-CMs monolayers. Phase, conduction velocity and activation maps were generated at baseline and after pacing (from 1000-to-400 ms). Flecainide (5 uM) was incubated for 1 min before pacing, and experiments were carried out as previously described.^{27,28}.

278

279 Statistical analyses. To determine the statistical power and minimum sample size in our 280 experiments, we did a power calculation using R base "power.t.test" or "power.anova.test" 281 function depending on data analysis. We used a significance level (alfa=0.05), power (1-282 beta=80%), the estimated difference between control and experimental data for t-test, and 283 estimated variances for ANOVA. We used GraphPad Prism software versions 7.0 and 8.0. 284 For non-Gaussian distributions, we applied the non-parametric Mann-Whitney test. We 285 used one- or two-way ANOVA corrected by Sídák's multiple comparisons test. We used 286 Grubb's test for analysis of outliers. Data are expressed as mean ± SEM, and differences are considered significant at p<0.05 (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). Note 287 288 that "N" refers to the number of mice or hiPSC-CMs differentiations used and "n" to the 289 number of cells analyzed per mouse or monolayer.

It is made available under a CC-BY-NC 4.0 International license .

290 Results

291

292 Ventricular arrhythmias persist in ATS1 patients despite flecainide therapy.

293 We systematically scanned the existing ATS1 literature assessing the effects of an 294 empirical, "one-size-fits-all" antiarrhythmic treatment, specially the use of class-Ic AADs 295 flecainide or propatenone, either alone or in combination with β -blockers. Our analysis 296 included both genders, all age ranges and diverse origins, while specifically excluding 297 those with structural or ischemic heart disease. The search yielded a limited number of 298 publications (23), most of which were isolated case reports (~87%) or small series (less 299 than 12 patients; ~13%), without any follow-up report. We evaluated the cardiac 300 phenotype, therapy and clinical response in a total of 53 documented patients each 301 carrying one of more than 20 different Kir2.1 loss-of-function mutations (Table 1). We incorporate a recently published study¹⁴ including a Kir2.1^{C122Y} proband, who presented 302 several syncopal polymorphic VT and suffered three proper ICD shocks between ages 25-303 304 35 under sodium channel blocker administration. A Holter trace (Figure 1A) shows an 305 electrogram with long-short coupling initiating polymorphic VT (PVT) suggesting either 306 ineffective therapy or a drug's proarrhythmic effect.

307 We also reproduce previously unreported tracings from two members, mother and 308 daughter, of a Spanish family of Caucasian origin with a final diagnosis of ATS1. Both 309 patients came to the consult of one of the authors (EZ) more than a decade after being 310 studied in other centers and treated ineffectively with multiple drug combinations. Both 311 carried a heterozygous missense KCNJ2 variant (c.644 G>A, Gly215Asp (G215D)) previously reported to disrupt Kir2.1-PIP₂ interactions.²⁹ The mother, patient I-1, was a 312 313 female who experienced worsening dyspnea and fatigue in their 60's (Case 1 in Table 1). 314 The ECG showed high burden ventricular extrasystoles (VE) and bidirectional VT (Figure **1B**, *upper panel*). The patient initially refused β-blocker treatment and was started on 315 316 flecainide (100 mg per day), but there was no improvement. Flecainide was subsequently 317 combined with small dose nadolol (20mg mg/day). While there was some improvement 318 the patient continued having high burden ventricular extrasystoles (from 3.2 to 18%) and 319 bidirectional VT (Figure 1B, middle panel). Flecainide was then switched to propatenone 320 (225 mg/kg/day), which led to another hospital admission due to non-syncopal dizziness 321 and continued high VA burden (11.2% with NSVT) (Figure 1B, bottom panel). The patient 322 experienced intolerance to mexiletine (7.7 mg per day), and after rejecting ICD 323 implantation, she is under nadolol alone, but continues with multiple ventricular 324 extrasystoles (up to 32%) and NSVT (Figure 1B) including self-limiting AF (<5 min).

325 The daughter, patient II-1, was initially referred to the hospital in their 20's for 326 syncope and multiple VEs (Case 1-daughter in Table 1). Nadolol (20mg) combined with 327 flecainide (100 mg/day) partially reduced in VE burden that finally led to a syncope and an 328 ICD was implanted. Treatment was maintained and resulted in a self-limiting VT episode. 329 Medication was changed to nadolol (20mg) and propafenone (375mg per day). She has 330 not reported syncope since then and the NSVT burden has declined from 35% under 331 flecainide to 10% with propatenone. Actually, she remains clinically more stable, but the 332 arrhythmias have not completely disappeared.

We also present the case of an ATS1 male proband in their 40's carrying the PIP₂-333 associated Kir2.1^{R67W} mutation (Case 2 in Table 1).³⁰ The patient exhibited characteristic 334 335 dysmorphic features including clinodactyly and micrognathia, and had experienced 336 periodic muscle paralysis since the age of 8, particularly during intense physical activity. 337 Initial treatment consisted of nadolol (120 mg/day) and acetazolamide (250 mg/day). 338 Holter monitoring revealed a QT interval of 480 ms (QTc 434 ms), prominent U waves, 339 high density polymorphic VE and 7 episodes of nonsustained BiVT. The 3-lead ECG time 340 series in **Figure 1C** shows frequent premature ventricular complexes and the Holter 341 fragment at the bottom shows an episode of polymorphic VT. Nadolol was then switched 342 to flecainide (100 mg/12h). However, while NSVT runs were no longer observed in 343 subsequent 24h-Holter monitoring, the patient continued with high density polymorphic VE 344 (>20%) and palpitations. Additionally, flecainide induced an asymptomatic 8-sec cardiac

345 pause and extreme sinus bradycardia, with an average heart rate of 50 bpm and a 346 minimum of 28 bpm. Currently, the patient is on nadolol (80mg/day) and has been 347 scheduled for left cardiac sympathetic denervation.

348 The Venn diagram presented in Figure 2 includes the 53 documented patients 349 reported in the 23 publications listed on Table 1. Only 23% of patients were successfully 350 treated with complete or greater than 90% VA suppression; 54% presented moderate 351 improvement during class-Ic AADs treatment, maintaining 20-50% of VA. More 352 importantly, in 23% of the cases, flecainide or propafenone were completely ineffective in 353 treating arrhythmias. Surprisingly, a total of 7 patients (13.5%) experienced an additional 354 non-fatal cardiac arrest in the presence of medication. Altogether, the results strongly 355 suggest that the use of flecainide and other class-Ic AADs is debatable in a significant 356 proportion of ATS1 patients due to great variability in outcomes and the potential for life-357 threatening proarrhythmia. Therefore, the intolerance to class-Ic AADs experienced by 358 many of these patients may depend on the specific ATS1-causative mutation, highlighting 359 the urgent need for molecular studies to investigate the underlying pathophysiological 360 mechanisms.

361

362 Class-Ic AADs alter cardiac conduction in ATS1 mouse models

363 The foregoing data demonstrate that the response of ATS1 patients to conventional AADs therapy is highly variable and may depend on the specific mutation 364 365 and other intermediate factors that affect the patient's electrical phenotype. To gain 366 insight into what such factors may be, we have generated five relevant cardiac-specific ATS1 mouse models using well-established AAV technology.¹⁹ In addition to wildtype 367 (Kir2.1^{WT}) mice, we generated mice with the cardiac-specific trafficking deficient Kir2.1^{Δ 314}</sub> mutation and the mutation Kir2.1^{C122Y} that disrupts Kir2.1-PIP₂ interaction, both 368 369 affecting Kir2.1-Na_V1.5 channelosomes and excitability.^{14,23} We also included mice with 370 the PIP₂-related Kir2.1^{G215D} and Kir2.1^{R67W} mutations found in our ATS1 patients. Further, 371 we incorporated the unrelated Kir2.1^{S136F}, which has been shown to alter the K⁺ selectivity 372 filter by modifying the highly conserved GYG motif.^{9,31,32} Surface ECG recordings obtained 373 374 8 weeks after AAV9-mediated inoculation showed that, compared with Kir2.1^{WT}, a single dose of flecainide (40 mg/kg; i.p.)²⁰ progressively prolonged the P wave, PR interval, and 375 QRS complex duration in all mutant mice over ~6 min. However, the effects were different 376 depending on the mutation, with Kir2.1^{R67W} > Kir2.1^{G215D} > Kir2.1^{Δ 314-315} > Kir2.1^{C122Y} > 377 Kir2.1^{S136F} (Figure 3A and Supplemental Figure 1). These data suggest that the varying 378 effects of each mutation reducing Kir2.1 and Nav1.5 membrane function, together with 379 drug-induced I_{Na} blockade synergized to prolong mutation-dependent intra-atrial (P-wave) 380 381 atrioventricular (PR interval) and intraventricular (QRS) conduction. Additionally, all 382 mutations prolonged the QTc interval to varying degrees, suggesting a differential flecainide-mediated I_{K1} response among mutant channels (Kir2.1^{C122Y} > Kir2.1^{G215D} > Kir2.1^{A314-315} > Kir2.1^{R67W} > Kir2.1^{S136F}). Propafenone (40 mg/Kg; i.p.) also prolonged all 383 384 ECG parameters compared with WT but to a lesser extent than flecainide, with the following pattern: Kir2.1^{Δ 314-315} > Kir2.1^{C122Y} > Kir2.1^{G215D} > Kir2.1^{R67W} > Kir2.1^{S136F} (Figure 385 386 387 3B).

Analysis of the ECGs revealed that in addition to altering the duration of intervals, many of the Kir2.1^{Δ314-315}, Kir2.1^{C122Y}, Kir2.1^{G215D} and Kir2.1^{R67W} mice developed spontaneous VA, some of them complex, when administered flecainide (**Figure 4**). **Figure 4A** shows data from a Kir2.1^{C122Y} mouse with frequent closely coupled PVCs with compensatory pauses. In **Figure 4B**, data from a Kir2.1^{G215D} animals show several runs of monomorphic NSVT. **Figure 4C** is a recording of a 9:1 sinoatrial block pattern in a Kir2.1^{Δ314-315} mouse. Finally, **Figure 4D** shows an example with frequent episodes of NSVT of variable duration in a Kir2.1^{R67W} mouse.

396

397 Flecainide fails to prevent arrhythmia inducibility in most ATS1 mutant mice

398 Our data compilation indicates that the cardiac electrical response of ATS1 399 patients to class-Ic AADs is highly variable. Propafenone has demonstrated limited

It is made available under a CC-BY-NC 4.0 International license .

success in managing VA compared to flecainide, and patients often require alternative
treatment options. Therefore, hereafter we focus solely on flecainide effects on
experimental animals and human cells. To test whether flecainide modifies arrhythmia
susceptibility in ATS1 mouse models we conducted *in-vivo* catheter-based, intracardiac
electrical stimulation experiments in all groups of animals (Figure 5). At baseline, all
mutant animals (Kir2.1^{Δ314-315}, 80%; Kir2.1^{C122Y}, 50%; Kir2.1^{G215D}, 50%, Kir2.1^{R67W}, 66,67%;
Kir2.1^{S136F}, 62.5%) were inducible for VA developing NSVT episodes of variable duration.
In contrast, only 1 out of 10 (10%) Kir2.1^{WT} mice was inducible (Figure 5A and B, top).

Flecainide administration was beneficial in Kir2.1^{S136F} mice, reducing VT inducibility 408 409 to 1 out of 8 animals (12.5%). However, a substantial increase in NSVT inducibility was 410 demonstrated in the rest of mutant mice after a single dose of flecainide (40 mg/Kg; i.p.) (**Figure 5B bottom**). In the presence of the drug, 70% of Kir2.1^{Δ 314-315}, 62.5% of Kir2.1^{C122Y}, 83,34% of Kir2.1^{G215D}; 100% of Kir2.1^{R67W}; but only 10% of Kir2.1^{WT} mice were 411 412 NSVT inducible. Importantly, although at baseline the mean duration of NSTV did not 413 414 exceed 1 sec in any of the mutant mice, a single dose of 40 mg/Kg flecainide increased 415 the duration of the induced VA to more than one second in all, except Kir2.1^{G215D} and 416 Kir2.1^{S136F} mutant mice (Figure 5C and D). Such a variable response to flecainide 417 resembles the heterogeneous clinical outcomes observed in ATS1 patients (Table 1).

418 We did observe significant alterations in sinus node function upon ventricular 419 intracardiac stimulation in all mutant mice. We measured sinus node recovery time 420 (SNRT) as the interval between the last pacing stimulus and the first atrial complex of 421 sinus origin in recordings whose response to intracardiac stimulation was not arrhythmogenic (Supplemental Figure 2). At baseline, SNRT was longer in Kir2.1⁽³¹⁴⁻³¹⁵⁾, 422 Kir2.1^{C122Y} and Kir2.1^{R67W} mice than Kir2.1^{WT} (**Supplemental Figure 2A**; SNRT, 280 ± 98 ms in Kir2.1^{Δ 314-315}; 327 ± 65 ms in Kir2.1^{C122Y}; 213 ± 69 ms in Kir2.1^{G215D}; 291 ± 83 ms in Kir2.1^{R67W}; and 196 ± 49 ms in Kir2.1^{S136F}; vs 218 ± 48 ms in Kir2.1^{WT} mice). Notably, flecainide led to a significant SNRT increase in Kir2.1^{Δ 314-315}, Kir2.1^{C122Y} and Kir2.1^{R67W} 423 424 425 426 427 mice, suggesting impaired sino-atrial excitability and conduction. In contrast, SNRT in Kir2.1^{WT}, Kir2.1^{G215D} and Kir2.1^{S136F} mice showed no significant change compared to pre-428 treatment values (**Supplemental Figure 2B**; Kir2.1^{A314-315}, 340 ± 116 ms; Kir2.1^{C122Y}, 462 ± 182 ms; Kir2.1^{G215D}, 240 ± 83 ms; Kir2.1^{R67W}, 502 ± 192 ms; and Kir2.1^{S136F}, 218 ± 76 ms</sup> 429 430 ; vs Kir2.1^{WT}, 224 ± 51 ms). While demonstrating therapeutic promise in Kir2.1^{S136F} 431 432 animals, the results suggest that flecainide potentially harms sinus node function in Kir2.1⁴³¹⁴⁻³¹⁵, Kir2.1^{C122Y} and Kir2.1^{R67W} mice. In addition, the ECG also revealed 433 prolonged P wave duration (Figure 3), suggesting delayed conduction through 434 435 Bachmann's bundle and the interatrial pathways, which is commonly associated with 436 AF.³³ Altogether, these results demonstrate a high variability in response to flecainide and suggest that susceptibility to proarrhythmia is dependent on the specific mutation. Thus, 437 438 understanding the intricacies of flecainide's actions in diverse genetic contexts is crucial 439 for refining arrhythmia management strategies and improving ATS1 patient care.

440

441 Flecainide impairs Kir2.1-Na_v1.5 channelosome function in mutant cardiomyocytes

Flecainide and propatenone have been shown to increase I_{K1} by interfering with 442 polyamine blockade in heterologous HEK293 cells expressing Kir2.1^{WT} channels,^{34,35} but 443 444 this effect has not been demonstrated in adult cardiomyocytes. To gain insight into the 445 ionic mechanisms of the proarrhythmic effects of flecainide in some of the ATS1 mice, we used equimolar therapeutic concentrations²¹ of the drug in patch-clamp experiments 446 focusing on I_{K1} and I_{Na} (Figure 6). We abstained from analyzing isolated Kir2.1^{Δ 314-315} 447 cardiomyocytes due to the severe impact on I_{K1} , which was completely absent.²⁰ 448 Superfusion of flecainide (10 μ M) slightly increased I_{K1} in Kir2.1^{WT} and Kir2.1^{S136F} 449 cardiomyocytes (Figure 6A). However, contrary to expected, this drug significantly 450 reduced I_{K1} in Kir2.1^{C122Y} and Kir2.1^{R67W} cardiomyocytes. Flecainide did not modify I_{K1} in 451 Kir2.1^{G215D} cardiomyocytes, as shown by the I/V plots and the I_{K1} slope values measured 452 between -140 and -50 mV (Figure 6A and C). Notably, in Kir2.1^{G215D} cardiomyocytes, 453 454 flecainide produced a small increase in the outward current, an effect that was nonexistent

at baseline, although it did not exceed the levels observed in mutant Kir2.1^{C122Y} and 455 Kir2.1^{R67W} cardiomyocytes (Figure 6D). On the other hand, compared to Kir2.1^{WT}, peak I_{Na} 456 density was significantly reduced only in Kir2.1^{C122Y} cardiomyocytes at baseline (Figure 457 458 **6B**). However, whereas 10 μ M flecainide reduced I_{Na} density by ~48% in Kir2.1^{WT}, the drug further decreased it in Kir2.1^{C122Y} (~62%), and Kir2.1^{R67W} (~66%) cardiomyocytes, showing a weaker effect over Kir2.1^{G215D} (~52%) and Kir2.1^{S136F} (~53%) cells (**Figure 6E**-459 460 **F**). These data further demonstrate that ATS1 mutants differentially modify I_{K1} and I_{Na} 461 462 densities at baseline and under flecainide administration. Thus, our results reinforce the 463 hypothesis that conduction disturbances and arrhythmias in ATS1 patients are not only 464 due to I_{K1} and RMP defects but also reduced excitability exacerbated by flecainide.

465

466 **ATS1 patient-specific iPSC-CMs are highly inducible for re-entrant arrhythmias**

We generated hiPSC-CM monolayers from consenting ATS1 patients carrying 467 Kir2.1^{C122Y}, Kir2.1^{R67W} and Kir2.1^{G215D} mutations (see Supplementary Methods). We 468 469 conducted optical mapping experiments to validate our previous experiments and better 470 understand the variable electrophysiological phenotypes of the patients in response to 471 flecainide. Importantly, we used a CRISPR-mediated genetically corrected isogenic 472 control (IC) for all three patient-specific hiPSC-CM to fully assess the contribution of Kir2.1 473 mutations to arrhythmia. We carried out optical mapping experiments using the voltage-474 sensitive fluorescent dye FluoVolt in monolayers paced at basic cycle lengths (BCL) 475 between 400 and 1000 ms. To better understand the underlying mechanism(s) of 476 flecainide-induced arrhythmogenesis, mutant and IC monolayers were superfused with 5 477 µM flecainide. CV restitution curves constructed from color phase maps displayed slower 478 velocities in C122Y iPSC-CMs monolayers compared to IC. Impressively, the CV was 479 highly reduced in C122Y monolayers after flecainide superfusion (Figure 7B). 480 Additionally, flecainide induced non-sustained re-entrant activity with complete rotations followed by spontaneous termination in patient-specific Kir2.1^{C122Y}, Kir2.1^{R67W} and 481 482 Kir2.1^{G215D} iPSC-CMs (Figure 7C). Mutant iPSC-CMs monolayers were more inducible for 483 re-entrant arrhythmias compared to ICs (6 out of 11, 54.5% in C122Y iPSC-CMs vs 2 out 484 of 11, 18.2% in IC; 6 out of 11, 54.5% in R67W vs 3 out 9, 33.3% in IC; 7 out of 11, 63.6% 485 in G215D vs 5 out of 11, 45.5% in IC) (Figure 7D). Most importantly, flecainide superfusion resulted in an increased rate of rotor generation in C122Y, and R67W 486 487 monolayers (rotors; 8 out of 11, 72.7% in C122Y vs 4 out of 14, 28.6% in IC; 8 out of 11, 72.7% in R67W vs 2 out of 6, 33.3% in IC). However, while flecainide eliminated 488 489 arrhythmias in IC monolayers (5 out of 11, or 45,5% rotors in untreated G215D IC vs 3 out 490 of 10, or 30% rotors in flecainide-treated G215D IC), it did not alter arrhythmia inducibility 491 in G215D iPSC-CMs; i.e., rotors were maintained during flecainide superfusion (7 out of 492 11, 63.6% in non-treated G215D vs 7 out of 11, 63.6% in flecainide-treated cultures) 493 (Figure 7D). Taken together, these data demonstrate that flecainide exacerbates the 494 already abnormal conduction in patient-specific iPSC-CMs^{C122Y} monolayers, leading to 495 reentry and polymorphic tachycardia. However, the molecular mechanisms underlying 496 arrhythmia inducibility and the ineffectiveness of flecainide in R67W and G215D iPSC-CM 497 monolayers, respectively, remain unclear and suggest more complex mechanisms that 498 are beyond the scope of this study.

499

500 ATS1 mutations differentially alter flecainide-to-Kir2.1 molecular docking

501 Previous computational studies have predicted that flecainide and propafenone 502 share a common binding site within the tetrameric Kir2.1 channel determined by a pharmacophore involving Cys₃₁₁ in the cytosolic space.³⁴ However, it has not been 503 determined whether Kir2.1 mutations may differentially reorganize the global structure of 504 505 the Kir2.1 channel and destabilize the pharmacophore binding site determined by Cy_{311} , 506 interfering with flecainide binding. In line with this, recent findings show that the 507 extracellular Cys122-to-Cys154 disulphide bond breaks disrupt Kir2.1-PIP2 interaction in the cytosolic-transmembrane region, which is distant from the location of the Kir2.1^{C122Y} 508 mutation.¹⁴ To test the above hypothesis, we used *in-silico* molecular docking modeling to 509

510 derive predictions of the molecular interaction of the mutated Kir2.1^{C122Y} channel and 511 flecainide in the Cys₃₁₁-mediated pharmacophore.

Our simulations revealed that Kir2.1^{WT} channels exhibit a substantially enhanced 512 513 binding affinity to flecainide in the presence of PIP₂, which is crucial for stabilizing in the 514 open state the narrowest part of the ion conduction pore (G-loop)^{36,37}. Defects in PIP₂ 515 binding are a major pathophysiological mechanism underlying the loss-of-function phenotype for several ATS1-associated mutations.^{9,38-40} The atomic binding sites for 516 517 flecainide and PIP₂ are closely located, and our simulation suggests that PIP₂ could help 518 accommodate flecainide molecules. Accordingly, in the absence of PIP₂ flecainide failed to bind to Cys₃₁₁ in Kir2.1^{WT} chains c and d in our simulations (Figure 8A). Impressively, a 519 520 complete set of flecainide molecules (one per Kir2.1^{WT} monomer) effectively integrated in the presence of PIP₂, exhibiting enhanced binding energy compared to its absence 521 522 (Figure 8B). This was evidenced by the Gibbs free-energy interface of flecainide binding 523 in the presence of PIP₂ in chains **a** (Δ dG-11.388) and **ab** (Δ dG-12.868 for chain **a** and 524 Δ dG-13.278 for chain b) vs chains **a** (Δ dG-9.948) and **ab** (Δ dG-9.979 for chain **a** and 525 $\Delta dG-9,102$ for chain **b**) in absence of PIP₂ (Figure 8A-B). Significantly, even though the Kir2.1^{C122Y} mutation alters the PIP₂ binding pocket,¹⁴ we observed that flecainide was fully 526 incorporated into the heterozygous mutant channels with a total of 2 PIP₂ molecules (one 527 per Kir2.1^{WT} monomer) (**Figure 8C**). 528

529 However, the Solvent Accessible Surface Area (SASA) of each Cys₃₁₁-530 pharmacophore in mutant C122Y heterotetramers exhibited significant variation along the 531 contiguous chain as we introduced flecainide molecules, indicating a substantial decrease 532 in the exposed surface area, which could potentially disrupt stable flecainide binding 533 (Figure 8D). The incorporation of a second flecainide molecule in the mutant 534 heterotetramer dramatically decreased the Gibs free-energy of the firstly incorporated 535 flecainide, as indicated the values for chains **a** (dG -13.24) and **ab** (Δ dG -3.027 for chain **a** 536 and ΔdG -9.575 for chain **b**) (Figure 8E). Comparative analysis of channel properties 537 revealed a similar pore length in WT (13.71 nm) and mutant (13.88 nm) heterotetramers, 538 but with more than 40% reduction in maxRadius (5.69 nm in WT vs. 3.27 nm in mutant 539 heterotetramer), suggesting channel constriction in the presence of flecainide (Figure 8E). In contrast, simulation of the Kir2.1^{S136F} mutant heterotetramer did not disrupt the Cys₃₁₁ 540 541 binding pocket, and flecainide successfully incorporated in mutant heterotetramers showing similar channel properties and binding capacity to the Kir2.1^{WT} model (Figure 8E-542 543 F). Incorporation of a second flecainide molecule retained the Gibs free-energy of the 544 firstly incorporated flecainide for chains **a** (Δ dG -14.601) and **ab** (Δ dG -15.437 for chain **a** 545 and ΔdG -11.057 for chain b) (Figure 8E). Analysis of channel properties revealed a 546 similar maxRadius (5.43 nm) and an increased pore length (16.86 nm) compared to the Kir2.1^{WT} structure (**Figure 8F**). 547

548 Collectively, these *in silico* homology studies predict that the Cys₃₁₁ binding pocket 549 is not conserved in mutant Kir2.1 channels. Depending on the specific mutation, the 550 Cys₃₁₁ binding pocket may undergo unique atomic rearrangements that affect both the 551 accessibility and energetic stability of flecainide molecules. This could potentially disrupt 552 the dynamics of flecainide binding, leading to different outcomes for channel function 553 depending on the particular ATS1 mutation.

554

555 **Discussion**

556 Flecainide received Food and Drug Administration (FDA) approval in 1984 for the 557 treatment of sustained VT. Subsequently, the Cardiac Arrhythmia Suppression Trial 558 (CAST) found that the drug was proarrhythmic and associated with excess all-cause mortality in patients with structural heart disease.⁴¹ Since then, class-lc AADs are 559 560 contraindicated in patients with coronary heart disease or chronic congestive heart failure. Class-Ic AADs are potent Na⁺ channel blockers that produce profound reductions in 561 conduction velocity (CV)^{42,43} and facilitate reentry, which explains their proarrhythmic 562 effect.⁴⁴ These agents do not often suppress sustained VA induction by programmed 563 stimulation.^{45,46} They raise the defibrillation threshold in experimental models,^{47,48} and their 564

use has been associated with incessant VT resistant to cardioversion.^{49,50} On the other 565 566 hand, both flecainide and propafenone have been indicated for supraventricular 567 arrhythmias, including atrial fibrillation (AF). To the best of our knowledge, the mechanism 568 has not been elucidated. Paradoxically, some investigators attribute such effects to 569 chamber-specific differences with greater flecainide inhibition of atrial I_{Na}, leading to higher reduction of both maximum AP upstroke velocity and CV in atrial tissue.⁵¹ Such an 570 interpretation seems counter to the well-established knowledge that reduced maximum 571 572 AP upstroke velocity and slowed conduction are pro-arrhythmic. Clinical and molecular 573 evidence suggest that flecainide could potentially promote arrhythmias even in patients 574 with structurally normal hearts, including reports of TdP and life-threatening PVT without coronary artery disease or heart failure.^{52,53} Despite these risks, class-Ic AADs have been 575 successfully used to treat hundreds of patients, and clinical guidelines continue to recommend them for specific arrhythmogenic cardiac diseases.^{7,8,54,55} 576 577

578 ATS1 is a rare disease that may lead to life-threatening VA and SCD without affecting heart structure³. More than 90 ATS1-associated autosomal dominant mutations 579 580 have been identified in the Ki2.1 protein. However, the molecular mechanisms are not 581 fully understood, and variability in phenotype severity, even within the same family³¹, 582 complicates treatment. Current antiarrhythmic therapies include β-blockers and class-Ic 583 AADs. The use of β -blockers has been derived from an early view that considered ATS1 584 as a variant of LQTS¹, and from the assumption that patients would respond to antiadrenergic interventions, despite the lack of robust mechanistic underpinnings. In 585 586 addition, a common treatment for ATS1 is flecainide or propafenone alone or in combination with β-blockers.⁵⁶⁻⁵⁹ The use of class-Ic AADs in patients with ATS1 started 587 588 with a report suggesting that flecainide effectively suppressed isolated PVCs and NSVT.⁶⁰ 589 Since then clinical guidelines recommend combinations of β-blockers and traditional AADs like flecainide and propafenone.^{7,8} However, their efficacy and safety in treating ATS1 590 591 remain contentious, and emerging evidence suggests that they may be associated with 592 variable efficacy and potential proarrhythmic effects.

593 To date, clinical guidelines fail to encourage standardization and homogeneity in 594 defining VA and therapeutic success, as these vary significantly among reports, 595 representing a mayor limitation of the available data. In support of this clinical observation, in our analysis of 53 ATS1 reported patients, flecainide and propafenone showed partial 596 597 effectiveness. As illustrated in Table 1, several brief reports have suggested that flecainide, alone or in combination with β -blockers suppresses VA in ATS1 patients.^{4,57,58,60-72} One study reported a 54-year-old male carrying the Kir2.1^{V302M} mutation 598 599 600 who experienced over 98% reduction in the number of PVCs (from a total of 15671 in 24h Holter monitoring) following flecainide treatment (200mg/day).⁶² However, a careful review 601 of clinical data from 48 patients showed a large patient-to-patient variability, mostly with 602 incomplete disappearance of VA under flecainide, which did not prevent life-threatening 603 arrhythmias and SCD (Table 1).^{4,57,62,64,73} In a case report of a 15-year-old boy carrying 604 the Kir2.1^{R218W} mutation, flecainide, mexiletine or nadolol monotherapy was ineffective in 605 preventing or reducing VA; only a combination of flecainide with verapamil reduced the 606 number of PVCs by about 87% (from 40846 per day).⁶⁴ In contrast, patients experienced 607 more moderate responses to flecainide alone. For example, ATS1 probands with the 608 Kir2.1^{R67Q} mutation showed only about 44% VA reduction (from a total of 19389 to 10854 609 PVCs) under flecainide (100 mg/day) combined with atenolol (50mg/day).⁷³ Additionally, 610 Miyamoto et al. reported that oral flecainide (100-200 mg/day) reduced VA in 10 patients, 611 who still maintained a ~30% VA burden.⁴¹ Several reports have shown that class-lc 612 AADs like flecainide and propafenone are ineffective in suppressing VA in ATS1.^{4,14,74-78} In 613 one case, propafenone was ineffective even when combined with verapamil, as the 614 proband still presented frequent episodes of bigeminy⁷⁵. Importantly, some studies have 615 reported cases of aborted SCD in patients with ATS1 who received an external 616 defibrillation or an ICD shock under treatment with flecainide or propafenone.^{4,14,60,72,74,77} 617 618 Although flecainide was effective in reducing the high burden of VA in one patient, Bokenkamp et al. reported one appropriate ICD shock for Torsades de Pointes (TdP) 619

620 tachycardia after three years under flecainide. In contrast, the patient's sister was 621 asymptomatic carrying the same Kir2.1^{R218W} mutation.⁶⁰ In the series of Delannoy et al, 622 one patient experienced a non-fatal cardiac arrest related to NSVT despite β-blockers and 623 flecainide treatment.⁷⁷ Similarly, Mazzanti et al. reported that the combination of these 624 drugs usually fails to reduce arrhythmias in ATS1.⁴ Interestingly, in Mazzanti's series 2 out 625 of 12 monitored probands experienced non-fatal cardiac arrest while on treatment⁴, but it 626 remains unclear whether this was due to proarrhythmia or merely ineffective therapy.

627 In our analysis, more than 20 loss-of-function Kir2.1 mutations were associated 628 with highly variable phenotypes (**Table 1**). This suggests that the molecular mechanisms 629 underlying the increased susceptibility to arrhythmias and SCD in ATS1 patients may 630 differ based on the specific mutation, which is crucial in determining the response to 631 AADs. In addition, our animal and human cell experiments reinforce the idea that ion channel interactions within multiprotein complexes, including Kir2.1-Na_V1.5 channelosomes, likely contribute to the wide variety of clinical outcomes.^{31,79-81} Therefore, 632 633 634 the molecular and functional interactions between Kir2.1-Nav1.5 indicates that ATS1 635 should no longer be considered in simplistic terms as a "monogenic" disorder. Reduction 636 in I_{K1} may directly affect the functional expression or biophysical properties of Na_V1.5 637 channels. I_{K1} reduction depolarizes the RMP and reduces the availability of Na_V1.5 for activation, with consequent impairment of cellular excitability and CV.⁸²⁻⁸⁴ However, recent 638 639 studies have shown that some mutation can also directly impact I_{Na} density, adding another layer of complexity to the electrophysiological alterations in ATS1. For instance, 640 the trafficking-deficient Kir2.1^{Δ 314-315} mutation and the Kir2.1^{C122Y} mutant that affects Kir2.1-641 PIP₂ interactions reduce Kir2.1 and Na_v1.5 protein levels at the cell membrane interfering 642 643 with both I_{K1} and I_{Na} densities in the cardiomyocyte. Both mutations lead to a slowconduction substrate favorable for cardiac arrhythmias.^{23,14} The balance between I_{Na} and 644 I_{K1} is a key determinant of the frequency and stability of ventricular rotors that ultimately 645 generate cardiac fibrillation and lead to SCD.⁸⁵ This delicate balance could be disrupted 646 647 by some ATS1 mutations at baseline and further exacerbated by class-Ic AADs. 648 Therefore, pharmacological treatment and clinical management should be carefully 649 tailored based on the specific mutation and individualized for each patient. However, to 650 our knowledge, no previous studies have evaluated the proarrhythmogenic consequences 651 of ATS1 and their impact on cardiac electrophysiology in response to class-Ic AADs.

652 Our finding revealed that flecainide and propafenone differentially prolonged the P wave duration and the PR, QRS and QTc intervals. They also increased VA inducibility 653 compared with Kir2.1^{WT}. In addition, flecainide promoted spontaneous VA and conduction 654 disturbances of varying types (Figure 4), including NSVT, atrioventricular (AV) block, and 655 long-short coupling PVCs, which have been previously associated with Purkinje fiber 656 dysfunction.⁸⁶ Altogether, these observations support the presence of different mutant-657 dependent mechanism, consistent with our hypothesis. Further, voltage-clamp 658 experiments revealed that flecainide increased I_{K1} density in Kir2.1^{WT} cardiomyocytes, as 659 previously described in HEK293 cells.^{34,35} However, in support of our hypothesis, the 660 effects of flecainide were different in cardiomyocytes expressing mutant channels (**Figure 6**). While Kir2.1^{S136F} responded similar to Kir2.1^{WT}, flecainide resulted ineffective in recovering the already decreased I_{K1} of Kir2.1^{G215D} cardiomyocytes. Interestingly, in both 661 662 663 Kir2.1^{R67W} and Kir2.1^{C122Y}, I_{K1} density was significantly reduced both under basal 664 conditions and in the presence of flecainide, which emphasizes I_{K1} blockade as a pro-665 arrhythmic mechanism of flecainide and a possible mechanism for prolonged QTc. 666 Similarly, the class III AAD amiodarone blocks I_{K1}^{87} and likely reduces excitability by 667 depolarizing the RMP giving a rationale for an increased risk of life-threatening arrhythmic 668 events in ATS1 patients. As Mazzanti et al also suggested, amiodarone may be pro-669 670 arrhythmic and should be avoided in ATS1 patients.⁴ Flecainide also exacerbated the reduction of I_{Na} density despite normal channel trafficking in Kir2.1^{C122Y} and Kir2.1^{R67W}, and 671 with great dispersion in Kir2.1^{G215D} mutant cardiomyocytes, which suggests heterogeneity 672 673 that contributes to proarrhythmia. Accordingly, in ATS1 patient-specific iPSC-CM 674 monolayers flecainide reduced CV in C122Y monolayers. Nevertheless, based on the

above findings, flecainide was ineffective in modifying the high rotor incidence in G215D
 cultures compared to baseline but increased in C122Y and R67W, supporting the drug's
 proarrhythmic effect.

678 Flecainide was originally characterized as a potent Na⁺ channel blocker that produce profound reductions in conduction velocity (CV),^{42,43}, but flecainide can also affect ionic currents governing ventricular repolarization,⁸⁸⁻⁹¹ although the molecular 679 680 mechanisms are poorly understood. Clinical observations support the notion that cardiac 681 electrical instability during flecainide treatment may be determined by defects in ventricular repolarization.^{92:95} Flecainide blocks the transient outward K⁺ current (I_{to}) in a 682 683 684 concentration-dependent manner, and some experimental studies attribute its 685 proarrhythmic effect in structurally normal hearts to increased spatial repolarization gradients⁹⁶ brought about by varying I_{to} expression across the myocardial wall.⁹⁷ But, 686 flecainide can also induce arrhythmia by increasing repolarization heterogeneities at the 687 level of the Purkinje fiber-ventricular muscle junction⁹⁸. Non-uniform expression of the 688 689 delayed rectifier K⁺ channels throughout the ventricular epicardium may also contribute to 690 dissimilar flecainide-induced APD lengthening in the left vs right ventricles.^{99,100} In 691 addition, flecainide modulates ryanodine receptor type 2 (RyR2) activity and inhibits the RyR2 open state to prevent diastolic Ca²⁺ waves that trigger arrhythmias.^{7,101,102}. 692 Flecainide might also modify the recently demonstrated SR microdomain of functional 693 Kir2.1 channels¹⁰³ that provide countercurrent to SERCA-mediated Ca2⁺ influx, potentially 694 altering Ca²⁺ handling, which may contribute to proarrhythmia in ATS1.²³ More studies 695 would be needed to assess the mutant-dependent contribution on Ca²⁺ homeostasis and 696 VA in flecainide-treated ATS1 patients. 697

While flecainide and propatenone interact with Cys₃₁₁ in the Kir2.1^{WT} subunits and 698 699 reduce polyamine-induced inward rectification, it remains unclear how mutant ATS1 channels impact the Cys₃₁₁ pharmacophore. Our in-silico molecular docking experiments 700 indicate that, unlike Kir2.1^{WT} channels, the Cys₃₁₁ binding pocket is not conserved in ATS1 701 702 mutant heterotetramers. This might disrupt the dynamic maintenance of flecainide binding 703 with unexpected consequences, potentially leading to channel closure and arrhythmias in 704 a subset of mutant channels, as we observed *in-vivo*. Interestingly, our in-silico studies 705 also predict that the Kir2.1-PIP₂ interaction energetically stabilizes the binding of flecainide 706 to the Kir2.1 channel. These findings suggest that mutations like C122Y, R67W, and G215D that disrupt Kir2.1-PIP₂ interactions^{9,14} could result in less favorable outcomes 707 708 compared to mutations like S136F, which do not interfere with this interaction but affect filter-selectivity properties.9,31,32 709 However, further studies are required to elucidate 710 whether mutation-induced disruption of Kir2.1-PIP₂ interactions is a key factor in the pro-711 arrhythmogenic effects of flecainide, which would lead to its contraindication in patients 712 carrying such mutations. Studies should also explore the molecular effects of 713 incorporating others AADs alone or in combination with β-adrenergic blocking drugs.

714 The results of our study underscore the need for a cautious re-evaluation of class-715 Ic AADs in ATS1 patients to achieve optimal treatment outcomes and minimize adverse 716 effects. Our results suggest that Kir2.1 mutations should not only be classified according 717 to their location in the channel structure but also based on their functional implications at the subcellular and cellular levels. In this sense, cardiac excitability is likely to be 718 dramatically reduced in ATS1 patients carrying the trafficking-deficient Kir2.1 A314-315 719 720 mutation, for whom we suggest direct exclusion of sodium channel blockers like flecainide 721 and propafenone, because of the high risk of arrhythmias. The same would be expected 722 for the Kir2.1^{C122Y} mutation which, despite reaching the sarcolemma, its structural changes lead to its Kir2.1-Na_v1.5 channelosome degradation.¹⁴ Conversely, patients carrying 723 mutations like Kir2.1^{S136F}, which does not reduce excitability and CV, might benefit from 724 725 the use of currently available AADs as demonstrated. In other words, a specific 726 combination of β -blockers and flecainide might be appropriate for ATS1-causing mutations 727 that alter the conformation of the channel, but not for mutations that affect Kir2.1 728 trafficking or others that lead to a decrease in I_{Na} density.

729

It is made available under a CC-BY-NC 4.0 International license .

730 Limitations

731 other rare disease, implementing evidence-based therapeutic Like anv 732 interventions for ATS1 presents significant challenges. Conducting conventional 733 randomized controlled trials on ATS1 is particularly difficult due to the minimal number of 734 patients worldwide. Unfortunately, the reported data often lack uniformity in key details, 735 such as treatment duration, dosages and routes of administration. As such, after 736 exhaustively searching the literature, we summarized data from only 23 publications 737 containing isolated ATS1 case reports or small series without follow-up. Our study is 738 limited to assessing the effects of an empirical, "one-size-fits-all" antiarrhythmic treatment 739 of patients of both genders, all age ranges and diverse origins based on flecainide and 740 other class-Ic AADs. Such limitations notwithstanding, we demonstrate that the cardiac 741 electrical response of ATS1 patients to class-Ic AADs is highly variable, and at times 742 contrary to anticipated. While some patients benefit from the use of these drugs, others do 743 not, and yet others may get worse. The results support our hypothesis that the effect of 744 class-lc AAD treatment in a given ATS1 patient will depend on the precise 745 electrophysiological consequences of the Kir2.1 loss-of-function mutation. The hypothesis 746 is further supported by experiments in a small but highly relevant group of mutant mouse 747 models, iPSC-CMs from three different ATS1 patients and in-silico simulations 748 demonstrating a significant hierarchy in the mutation-induced arrhythmic phenotype and 749 molecular effects in response to flecainide treatment. While well outside of the scope of 750 this study, we are well aware of the need to assess the role of channels other than Kir2.1 751 and Na_V1.5 and the effects of spatial heterogeneities to establish more rigorously the 752 mechanisms of mutation-induced arrhythmias and their exacerbation by the drugs. 753 Nevertheless, our experimental results strongly support that flecainide-induced pro-754 arrhythmia might be at least in part due to specific reductions in both I_{K1} and I_{Na} , which 755 significantly impairs excitability as demonstrated by the prolongation of the PR and QRS 756 intervals in the mutant mice and the slowing of CV in the mutant iPSC-CMs.

757

758 Conclusion

759 The results presented here open new horizons for the pharmacologic management 760 of ATS1 patients. They demonstrate for the first time that whether or not class-Ic AADs 761 will benefit a given ATS1 patient will depend on the precise electrophysiological 762 consequences of specific Kir2.1 mutation. As such, we must no longer correct only the 763 lack of function of the mutated channel, but also consider the possible repercussions on 764 the molecular interactors of the channel that each particular mutation entails. A deeper 765 understanding of the different arrhythmogenic mechanisms associated with different ATS1 766 mutations should open new pathways for personalized treatments of patients suffering 767 from these devastating channelopathies. Our results emphasize the need to gain a deeper 768 understanding of the specific pharmacologic regulation of Kir2.1 mutations, elucidate the 769 pathophysiology of arrhythmias in individual patients with ATS1, and identify an effective, 770 more personalized therapy that reduces individual proarrhythmia risk. Therefore, studies 771 on the usefulness of already approved drugs and their derivatives for the treatment of 772 diseases such as ATS1 should continue to improve the stratification of affected patients. 773

It is made available under a CC-BY-NC 4.0 International license .

774 **ACKNOWLEDGEMENTS**

775 We thank the CNIC Viral Vectors Unit for producing the AAV9. Confocal experiments were 776 conducted at the CNIC Microscopy and Dynamic Imaging Unit. We thank the CNIC 777 Bioinformatics Unit for generating the *in-silico* homology modeling simulations, F-function 778 analysis, and helpful discussions. We also thank the Centro de Supercomputación de 779 Galicia (CESGA) for the use of the Finis Terrae III supercomputer to perform molecular 780 dynamics studies. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the 781 Ministerio de Ciencia, Innovación y Universidades (MICIU), and the Pro CNIC Foundation, 782 and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by 783 MICIN/AEI/10.13039/501100011033).

784

FUNDING: Supported by National heart, Lung and Blood Institute, NIH grant number 785 786 R01HL163943; Caixa Banking Foundation project code HR18-00304 La (LCF/PR/HR19/52160013); grants PI-FIS-2020 # PI20/01220 and PI-FIS-2023 # 787 788 PI23/01039 from Instituto de Salud Carlos III (ISCIII) and co-funded by Fondo Europeo de 789 Desarrollo Regional (FEDER), and by The European Union, respectively; grant PID2020-790 116935RB-I00 and BFU2016-75144-R funded by MCIN/AEI/10.13039/501100011033; 791 Fundación La Marató de TV3 (736/C/2020) "amb el suport de la Fundació La Marató de 792 TV3": CIBERCV (CB16/11/00458: CB/11/00222 to CV): European Union's Horizon 2020 793 grant agreement GA-965286; and Program S2022/BMD7229 -CM ARCADIA-CM funded 794 by Comunidad de Madrid; to JJ; Program S2022/BMD-7223 funded by Comunidad de CV), 795 Madrid, Grant PID2022-137214OB-C21 (to to CV: funded by 796 MCIN/AEI/10.13039/501100011033; The imaging studies were performed in the 797 TRIMA@CNIC node of the ICTS ReDIB Grant ICTS-2018-04-CNIC-16 funded by 798 MCIN/AEI /10.13039/501100011033 and ERDF; project EQC2018-005070-P funded by 799 MCIN/AEI /10.13039/501100011033 and FEDER. AIM-M holds an FPU contract 800 (FPU20/01569) from Ministerio de Universidades. JMRR holds an FPU contract 801 (FPU22/03253) from Ministerio de Universidades. LKG holds an FPI contract (PRE2018-802 083530), Ministerio de Economía y Competitividad de España co-funded by Fondo Social 803 Europeo, attached to Project SEV-2015-0505-18-2. IMC holds a PFIS contract 804 (FI21/00243) funded by Instituto de Salud Carlos III and Fondo Social Europeo Plus 805 (FSE+), 'co-funded by the European Union'. MLVP held contract PEJD-2019-PRE/BMD-806 15982 funded by Consejería de Educación e Investigación de la Comunidad de Madrid y 807 Fondo Social Europeo.

808

809 **DISCLOSURES**

810 None

811

812 AUTHOR CONTRIBUTION

813 F.M.C. and J.J. co-designed the experiments; F.M.C. performed most of the experiments; 814 A.I.M.M. and P.G.S. are authors for cellular electrophysiology; E.Z., and J.J.J. provided 815 clinical data, discussion and revisions; F.M. were in charge of in-silico homology modeling 816 and molecular docking studies; P.S.P., M.L.V. and A.T.G. cultivated iPSC-CMs cells; 817 L.K.G. and J.R.R performed optical mapping analysis; A.M., G.M.P., S.A.S., I.M.C., F.B.J., 818 A.B.B., C.V. provided technical support, discussions and revisions; F.M.C. and J.J. co-819 wrote the manuscript and conceived the study; J.J. provided funding; J.J. provided 820 supervision and revisions; All authors discussed the results and commented on and 821 approved the manuscript.

822

823 CORRESPONDING AUTHORS

824 Correspondence to José Jalife or Francisco M. Cruz.

825

826 SUPPLEMENTAL INFORMATION

- 827 Extended Materials & Methods
- 828 Supplementary Figures 1-2

It is made available under a CC-BY-NC 4.0 International license .

829 Supplementary Tables 1-2

It is made available under a CC-BY-NC 4.0 International license .

830 Figures legends

831 **Table 1: Response to class-lc AADs in ATS1 patients.**

Betailed analysis of 53 different probands shows a large variability from patient to patient.
Data reveal moderate, incomplete or ineffective responses to class-lc AADs in
suppressing ventricular arrhythmias (VA) in ATS1. The table incorporates demographic
information and clinical features of reviewed ATS1 cases, including age, sex, reported
mutation, cardiac phenotype, treatment, and response.

837

838 Figure 1. Arrhythmogenic responses to Ic class AADs in ATS1 patients

A: Recorded polymorphic ventricular tachycardia (VT) from an automated external defibrillator in Kir2.1^{C122Y} proband (II.2). Pedigree of the family is shown in the upper left square. **B**: Recorded polymorphic ventricular tachycardia (*upper panel*) and a high burden of non-sustained ventricular tachycardias (NSVT) in Kir2.1^{G215D} proband (I.2) under Flecainide + Nadolol (*middle panel*) or Propafenone + Nadolol (*bottom panel*). **C**: ECG from Kir2.1^{R67W} patient shows polymorphic VT. All Probands are indicated with a black arrow.

846

847 Figure 2. Class-Ic-based antiarrhythmic therapy in AST1.

A-B: Venn diagram (**A**) and schematic representation (**B**) of class-lc therapy response in ATS1 patients. Data show 23% of patients who benefited from a full or greater than 90% suppression of VA; 54% reported substantial but incomplete improvement during flecainide treatment, mostly maintaining 20 to 50% of VA. In 23% of patients, flecainide was completely ineffective; 13.5% experienced an additional non-fatal cardiac arrest with an appropriate ICD shock in the presence of flecainide.

854

Figure 3. ATS1 mice recapitulate the pathological ECG phenotype

856 A-B: Time-course after a single dose of flecainide (A) or propafenone (40 mg/Kg) (B) 857 reveals prolonged P wave, PR, QRS and QTc in Kir2.1 mutant animals compared to 858 controls (black). Every value represents the averaged P waves, PR, QRS and QTc 859 from consecutive beatings. Arrows indicate the time intervals ten of flecainide/propafenone administration. Representative beats of Kir2.1^{WT} (black), Kir2.1^{Δ314-} 860 ³¹⁵ (green), Kir2.1^{C122Y} (red), Kir2.1^{G215D} (purple), Kir2.1^{R67W} (blue) and Kir2.1^{S136F} (orange) 861 862 mice after 5 min of flecainide administration are also indicated. Statistical analysis by two-863 tailed ANOVA. * = p<0.05; ** = p<0.01; **** = p<0.0001.

864

865 Figure 4. Flecainide is proarrhythmic and alters cardiac conduction in ATS1 mice

Representative electrocardiograms (ECG) lead-II traces recordings in AAV-transduced Kir2.1^{C122Y} (A) animals showing frequent premature ventricular complexes (PVCs), Kir2.1^{G215D} (B) and Kir2.1^{A314-315} (C) animals showing atrioventricular block, and Kir2.1^{R67W}
(D) animals showing non-sustained ventricular tachycardia (NSVT) after flecainide administration.

871

872 Figure 5. Flecainide increases susceptibility to arrhythmias in ATS1 mutant mice.

A: Representative ECG lead-II traces after a train of intracardiac ventricular pulses in 873 AAV-transduced Kir2.1^{WT} (black; N=10), Kir2.1^{Δ 314-315} (green; N=8), Kir2.1^{C122Y} (red; N=8), Kir2.1^{G215D} (purple; N=6), Kir2.1^{R67W} (blue; N=6) and Kir2.1^{S136F} (orange; N=8) animals with 874 875 876 periods of polymorphic ventricular tachycardia (PVT) at baseline. A short duration of non-877 sustained ventricular tachycardias (NSTV) is indicated. B: Contingency plots showing the 878 number of animals with the arrhythmogenic response after intracardiac stimulation at 879 baseline (top) and under flecainide (20mg/Kg) (bottom). C: Representative ECG lead-II 880 trace showing longer NSVT runs after flecainide administration. D: Graph shows 881 ventricular tachycardias (VT) duration at baseline and under flecainide administration. Statistical analysis using the Fisher's exact test. * = p<0.05; ** = p<0.01; *** = p<0.001; 882 883 **** = p<0.0001

It is made available under a CC-BY-NC 4.0 International license .

884

885 Figure 6. Cardiac expression of ATS1 mutations alter mouse ventricle 886 electrophysiology in isolated cardiomyocytes.

A: Current-voltage (I/V) relationships of inward rectifying potassium current I_{K1} and **B**: I_{Na} density in Kir2.1^{WT} (black), Kir2.1^{Δ 314-315} (green), Kir2.1^{C122Y} (red), Kir2.1^{G215D} (purple), Kir2.1^{R67W} (blue) and Kir2.1^{S136F} (orange) cardiomyocytes at baseline and under flecainide superfusion. **C**: I_{K1} slope from -140 to -60 mV at baseline and under flecainide administration. **D**: Sodium density I_{Na} peak (pA/pF) at -35mV. **E**: Percentage of remaining I_{Na} density after flecainide inhibition. Statistical analyses were conducted using two-tailed ANOVA. * = p<0.05; ** = p<0.01; **** = p<0.001.

894

Figure 7. Flecainide leads to conduction defects and re-entrant arrhythmias in patient-specific iPSC-CMs.

897 A: Representative single camera pixel recording from an optical mapping experiment show velocity maps with 1 ms activation isochrones in patient-specific iPSC-CMs^{C122Y} 898 (red) and CRISPR-mediated isogenic control iPSC-CMs^{C122Y} (blue) hearts paced at a 899 900 basic cycle length (BCL) of 400 ms. The color bar indicates conduction velocity (CV; cm s-901 1). The white asterisks indicate the pacing point and the propagation direction is indicated 902 by the white arrow. B: Re-entrant arrhythmias from C122Y, G215D and R67W patient-903 specific iPSC-CMs monolayers under flecainide treatment. Below each map is a single 904 pixel recording revealing different patterns of monomorphic or polymorphic re-entrant 905 tachycardia maintained by one self-sustaining rotor. C: The CV restitution curve displayed slower velocities in iPSC-CMs^{C122Y} monolayers at all frequencies tested. All groups 906 907 presented slightly slower velocities at higher frequencies. Each value is the mean ± SEM 908 (N=5 differentiations; n indicates number of monolayers per condition; two-way ANOVA 909 corrected by Tukey's multiple comparisons test, * p<0.05; ** p<0.01; a=IC C122Y vs 910 C122Y; b= IC C122Y Fleca vs C122Y Fleca; c= IC C122Y vs 122Y Fleca; and d= IC 122Y 911 vs IC C122Y Fleca). D: Contingency plots of number of monolayers show arrhythmia 912 inducibility for each group. Data show a high rate of arrhythmia susceptibility in mutant 913 iPSC-CMs. Each value is the mean ± SEM (Fisher's exact test for contingency data).

914

915 Figure 8. Kir2.1 mutated channels display conformational alteration in the 916 pharmacophore binding site at Cys₃₁₁.

A: Tridimensional (3D) representation of Kir2.1^{WT} showing cavities C (magenta) and D 917 918 (vellow) in the absence (top) and presence (bottom) of PIP₂ molecules. Note that PIP₂ is 919 required for proper flecainide binding in c and d cavities. PIP₂ (red arrow) and flecainide 920 (blue arrow) are also indicated. B: 3D representation of flecainide binding in cavity a 921 (green) and **b** (blue) in the absence (top) and presence (bottom) of PIP_2 molecules in Kir2.1^{%T}. Gibbs free energy values are shown, being more stable in the presence of PIP₂. **C**: 3D representation of flecainide binding in Kir2.1^{C122Y} heterotetramer. Flecainide is fully 922 923 present in Kir2.1^{C122Y} heterotetramer. **D:** Solvent Accessible Surface Area (SASA) of each 924 Cys₃₁₁-pharmacophore in Kir2.1^{WT} (blue) and Kir2.1^{C122Y} (red) in sequential incorporation 925 flecainide molecules. E: Comparative table of Gibbs free energy values of flecainide 926 binding to each chain in Kir2.1^{WT}, Kir2.1^{C122Y} and Kir2.1^{S136F} channels. **F:** Schematic representation of Kir2.1^{WT} (top), Kir2.1^{C122Y} (middle) and Kir2.1^{S136F} (bottom) channel 927 928 929 showing a similar pore length (13.71 nm; 13.88 nm; and 16.86 nm) and maxRadius (5.69 930 nm; 3.27 nm; and 5.43 nm), respectively.

931

It is made available under a CC-BY-NC 4.0 International license .

932	Refere	ences
933	4	
934	1	I ristani-Firouzi, M. et al. Functional and clinical characterization of KCNJ2
935		mutations associated with LQT7 (Andersen syndrome). J Clin Invest 110, 381-388,
936	•	doi:10.1172/JCI15183 (2002).
937	2	Pegan, S., Arrabit, C., Slesinger, P. A. & Choe, S. Andersen's syndrome mutation
938		effects on the structure and assembly of the cytoplasmic domains of Kir2.1.
939	2	Biochemistry 45, 8599-8606, doi:10.1021/bio60653d (2006).
940	5	ristani-Firouzi, M. & Etheridge, S. P. Kir 2.1 channelopathies: the Andersen-Tawi
941	4	syndrome. Pflugers Arch 460, 289-294, doi:10.1007/s00424-010-0820-6 (2010).
942	4	Sundrama Tuna 1. LAm Call Cardia LZE, 1772, 1784, dai:10.1016/j.iaaa.2020.02.022
945		Syndrome Type 1. J Am Coll Caralol 75 , 1772-1784, doi:10.1016/j.jacc.2020.02.033
944	-	(2020).
945	5	Priori, S. G. <i>et al.</i> 2015 ESC Guidelines for the management of patients with
946		Ventricular arrnythmias and the prevention of sudden cardiac death: The Task
947		Force for the Management of Patients with Ventricular Armythmias and the
948		Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC).
949		Endorsed by: Association for European Paediatric and Congenital Cardiology
950		(ACPC). European nearc journal 56 , 2795-2867, doi:10.1095/eurnearcj/env516
951	c	(2013). Dichards S at al Standards and guidalines for the interpretation of seguence
952	0	variants, 5. <i>et al.</i> Standards and guidelines for the interpretation of sequence
955		Canation and Canamian and the Association for Malagular Dathalagy. Canat Mad
954		17 405 424 doi:10.1028/gim 2015.20 (2015)
955	7	Zannanfald K et al 2022 ESC Guidalinas for the management of nationts with
950	/	ventricular arrhythmias and the prevention of sudden cardiac death. <i>Eur Heart J</i>
958		43 3997_4126 doi:10.1093/eurbearti/ebac262 (2022)
959	8	Al-Khatih S M et al 2017 AHA/ACC/HRS guideline for management of natients
960	0	with ventricular arrhythmias and the prevention of sudden cardiac death. A
961		Report of the American College of Cardiology/American Heart Association Task
962		Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>
963		15 , e73-e189, doi:10.1016/j.hrthm.2017.10.036 (2018).
964	9	Moreno-Manuel, A. I. et al. Molecular stratification of arrhythmogenic
965		mechanisms in the Andersen Tawil syndrome. <i>Cardiovasc Res</i> 119 , 919-932,
966		doi:10.1093/cvr/cvac118 (2023).
967	10	Matamoros, M. <i>et al.</i> Nav1.5 N-terminal domain binding to alpha1-syntrophin
968		increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels.
969		<i>Cardiovasc Res</i> 110 , 279-290, doi:10.1093/cvr/cvw009 (2016).
970	11	Ponce-Balbuena, D. et al. Cardiac Kir2.1 and NaV1.5 Channels Traffic Together to
971		the Sarcolemma to Control Excitability. <i>Circ Res</i> 122 , 1501-1516,
972		doi:10.1161/CIRCRESAHA.117.311872 (2018).
973	12	Utrilla, R. G. et al. Kir2.1-Nav1.5 Channel Complexes Are Differently Regulated
974		than Kir2.1 and Nav1.5 Channels Alone. <i>Front Physiol</i> 8 , 903,
975		doi:10.3389/fphys.2017.00903 (2017).
976	13	Ma, D. et al. Golgi export of the Kir2.1 channel is driven by a trafficking signal
977		located within its tertiary structure. <i>Cell</i> 145, 1102-1115, doi:S0092-
978		8674(11)00649-0 [pii]
979	10.101	.6/j.cell.2011.06.007 (2011).

980	14	Cruz, F. M. <i>et al.</i> Extracellular Kir2.1(C122Y) Mutant Upsets Kir2.1-PIP(2) Bonds					
981		and Is Arrhythmogenic in Andersen-Tawil Syndrome. <i>Circ Res</i> 134 , e52-e71,					
982		doi:10.1161/CIRCRESAHA.123.323895 (2024).					
983	15	Tamargo, J., Delpón, E. in Cardiac Electrophysiology. 6th edn. (ed D. Zipes, Jalife,					
984		J.) 529-540 (2014).					
985	16	Kimura, H. et al. Phenotype variability in patients carrying KCNJ2 mutations. Circ					
986		Cardiovasc Genet 5, 344-353, doi:10.1161/CIRCGENETICS.111.962316					
987	CIRCG	ENETICS.111.962316 [pii] (2012).					
988	17	Xiao, X., Li, J. & Samulski, R. J. Production of high-titer recombinant adeno-					
989		associated virus vectors in the absence of helper adenovirus. J Virol 72, 2224-					
990		2232, doi:10.1128/JVI.72.3.2224-2232.1998 (1998).					
991	18	Hauswirth, W. W., Lewin, A. S., Zolotukhin, S. & Muzyczka, N. Production and					
992		purification of recombinant adeno-associated virus. <i>Methods Enzymol</i> 316 , 743-					
993		761, doi:10.1016/s0076-6879(00)16760-6 (2000).					
994	19	Cruz, F. M. et al. Exercise triggers ARVC phenotype in mice expressing a disease-					
995		causing mutated version of human plakophilin-2. <i>J Am Coll Cardiol</i> 65 , 1438-1450,					
996		doi:S0735-1097(15)00445-3 [pii]					
997	10.10	16/j.jacc.2015.01.045 (2015).					
998	20	Cerrone, M. et al. Sodium current deficit and arrhythmogenesis in a murine model					
999		of plakophilin-2 haploinsufficiency. <i>Cardiovasc Res</i> 95 , 460-468,					
1000		doi:10.1093/cvr/cvs218					
1001	cvs21	8 [pii] (2012).					
1002	21	Heath, B. M. <i>et al</i> . Translation of flecainide- and mexiletine-induced cardiac					
1003		sodium channel inhibition and ventricular conduction slowing from nonclinical					
1004		models to clinical. <i>J Pharmacol Toxicol Methods</i> 63 , 258-268,					
1005		doi:10.1016/j.vascn.2010.12.004 (2011).					
1006	22	Bao, Y. <i>et al.</i> Sch2b Deletion in Mice Results in Ventricular and Atrial Arrhythmias.					
1007	22	Circ Arrhythm Electrophysiol 9, doi:10.1161/CIRCEP.116.003923 (2016).					
1008	23	Macias, A. et al. Kir2.1 dystunction at the sarcolemma and the sarcoplasmic					
1009		1. Neture Cardiovaceular Research, doi:10.1028/s44161.022.00145.2.(2022)					
1010	24	1. Nature Caralovascular Research, doi:10.1038/s44161-022-00145-2 (2022).					
1011	24	rakanashi, K. & Yananaka, S. A decade of transcription factor-mediated					
1012		dei:10.1028/nrm 2016.8 (2016)					
1013	25	Lian X <i>et al.</i> Directed cardiomyocyte differentiation from human nurinotent stem					
1014	25	calls by modulating What/bata catenin signaling under fully defined conditions. Nat					
1015		Protoc 8 162-175 doi:10.1038/nprot 2012.150/2013)					
1010	26	Lian X <i>et al.</i> Robust cardiomyocyte differentiation from human nurinotent stem					
1017	20	cells via temporal modulation of canonical What signaling. Proc Natl Acad Sci 11 S A					
1010		109 F1848-1857 doi:10.1073/nnas.1200250109 (2012)					
1020	27	Herron T. J. Lee P. & Jalife J. Ontical imaging of voltage and calcium in cardiac					
1020	27	cells & tissues <i>Circ Res</i> 110 609-623 doi:10 1161/CIRCRESAHA 111 247494					
1021	110/4	/609 [nii] (2012)					
1022	28	limenez-Vazquez, F. N. <i>et al.</i> SNTA1 Gene Rescues Ion Channel Function in					
1023	20	Cardiomyocytes Derived from Induced Pluripotent Stem Cells Reprogrammed					
1025		from Muscular Dystrophy Patients with Arrhythmias <i>hioRxiv</i>					
1026		2022.2001.2025.477696, doi:10.1101/2022.01.25.477696 (2022).					
-							

1027	29	Hosaka, Y. et al. Function, subcellular localization and assembly of a novel
1028		mutation of KCNJ2 in Andersen's syndrome. <i>J Mol Cell Cardiol</i> 35 , 409-415,
1029		doi:10.1016/s0022-2828(03)00046-4 (2003).
1030	30	Andelfinger, G. et al. KCNJ2 mutation results in Andersen syndrome with sex-
1031		specific cardiac and skeletal muscle phenotypes. Am J Hum Genet 71 , 663-668,
1032		doi:10.1086/342360 (2002).
1033	31	Plaster, N. M. et al. Mutations in Kir2.1 cause the developmental and episodic
1034		electrical phenotypes of Andersen's syndrome. <i>Cell</i> 105 , 511-519,
1035		doi:10.1016/s0092-8674(01)00342-7 (2001).
1036	32	Zhang, L. <i>et al.</i> Electrocardiographic features in Andersen-Tawil syndrome patients
1037		with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2
1038		genotype. Circulation 111, 2720-2726, doi:10.1161/CIRCULATIONAHA.104.472498
1039		(2005).
1040	33	Leier, C. V., Meacham, J. A. & Schaal, S. F. Prolonged atrial conduction. A major
1041		predisposing factor for the development of atrial flutter. <i>Circulation</i> 57, 213-216,
1042		doi:10.1161/01.cir.57.2.213 (1978).
1043	34	Caballero, R. <i>et al.</i> Flecainide increases Kir2.1 currents by interacting with cysteine
1044		311, decreasing the polyamine-induced rectification. <i>Proc Natl Acad Sci U S A</i> 107 ,
1045		15631-15636, doi:10.1073/pnas.1004021107 (2010).
1046	35	Gomez, R. et al. Structural basis of drugs that increase cardiac inward rectifier
1047		Kir2.1 currents. <i>Cardiovasc Res</i> 104 , 337-346, doi:10.1093/cvr/cvu203 (2014).
1048	36	Hibino, H. <i>et al.</i> Inwardly rectifying potassium channels: their structure, function,
1049		and physiological roles. <i>Physiol Rev</i> 90, 291-366, doi:10.1152/physrev.00021.2009
1050		(2010).
1051	37	Fernandes, C. A. H. <i>et al.</i> Cryo-electron microscopy unveils unique structural
1052		features of the human Kir2.1 channel. <i>Sci Adv</i> 8 , eabq8489,
1053		doi:10.1126/sciadv.abq8489 (2022).
1054	38	Donaldson, M. R. et al. PIP2 binding residues of Kir2.1 are common targets of
1055		mutations causing Andersen syndrome. <i>Neurology</i> 60 , 1811-1816,
1056		doi:10.1212/01.wnl.0000072261.14060.47 (2003).
1057	39	Handklo-Jamal, R. et al. Andersen-Tawil Syndrome Is Associated With Impaired
1058		PIP(2) Regulation of the Potassium Channel Kir2.1. Front Pharmacol 11, 672,
1059		doi:10.3389/fphar.2020.00672 (2020).
1060	40	Lopes, C. M. et al. Alterations in conserved Kir channel-PIP2 interactions underlie
1061		channelopathies. <i>Neuron</i> 34 , 933-944, doi:10.1016/s0896-6273(02)00725-0
1062		(2002).
1063	41	Echt, D. S. et al. Mortality and morbidity in patients receiving encainide, flecainide,
1064		or placebo. The Cardiac Arrhythmia Suppression Trial. <i>N Engl J Med</i> 324 , 781-788,
1065		doi:10.1056/NEJM199103213241201 (1991).
1066	42	Morganroth, J. Risk factors for the development of proarrhythmic events. Am J
1067		<i>Cardiol</i> 59 , 32E-37E, doi:10.1016/0002-9149(87)90199-8 (1987).
1068	43	Horowitz, L. N., Greenspan, A. M., Rae, A. P., Kay, H. R. & Spielman, S. R.
1069		Proarrhythmic responses during electrophysiologic testing. Am J Cardiol 59, 45E-
1070		48E, doi:10.1016/0002-9149(87)90201-3 (1987).
1071	44	Soyka, L. F. Safety of encainide for the treatment of ventricular arrhythmias. Am J
1072		<i>Cardiol</i> 58 , 96C-103C, doi:10.1016/0002-9149(86)90111-6 (1986).

1073	45	Treatment of life-threatening ventricular tachycardia with encainide hydrochloride
1074		in patients with left ventricular dysfunction. The Encainide-Ventricular Tachycardia
1075		Study Group. Am J Cardiol 62 , 571-575, doi:10.1016/0002-9149(88)90657-1
1070	10	(1988). Disting F. V. et al. Eleccipides clastrophysicles is and entirguby threis properties in
1077	40	refrectory ventricular technical de l'ardial EE . 956.962, dei:10.1016/0002
1070		140(95)00726 v (1095)
10/9	47	9149(85)90720-X (1985).
1080	47	Fain, E. S., Dorian, P., Davy, J. W., Kates, K. E. & Winkle, R. A. Effects of encainide
1081		and its metabolites on energy requirements for defibrillation. <i>Circulation</i> 73 , 1334-
1082	18	Reiffel I A Coromilas I Zimmerman I M & Spotnitz H M Drug-device
1005	40	interactions: clinical considerations. Pacing Clin Electronhysiol 8, 369-373
1085		d_{0i} 10 1111/i 15/0-8159 1985 th05773 x (1985)
1005	10	Winkle R & Mason L W. Griffin L C & Ross D Malignant ventricular
1080	49	tachyarrhythmias associated with the use of encainide. Am Heart 1102, 857,864
1087		doi:10.1016/0002-8703(81)90036-3 (1981).
1089	50	Morganroth I & Horowitz I N Elecainide: its proarrhythmic effect and expected
1090	50	changes on the surface electrocardiogram Am I Cardiol 53 898-948
1091		doj:10 1016/0002-9149(84)90509-5 (1984)
1092	51	$S \cap B$ et al. Increased atrial effectiveness of flecainide conferred by altered
1093	01	bionhysical properties of sodium channels. I Mol Cell Cardiol 166, 23-35
1094		doj:10.1016/i vimcc 2022.01.009 (2022)
1095	52	Kim, H. S., Pak, H. N., Park, J. S. & Kim, S. S. Elecainide-associated bradycardia-
1096		dependent torsade de pointes: another potential mechanism of proarrhythmia
1097		Pacina Clin Electrophysiol 36 , e84-86, doi:10.1111/j.1540-8159.2010.02935.x
1098		(2013).
1099	53	Oguavo, K. N., Ovetavo, O. O., Costa, S. M. & Mixon, T. A. An unusual case of
1100		flecainide-induced OT prolongation leading to cardiac arrest. <i>Pharmacotherapy</i>
1101		34 , e30-33, doi:10.1002/phar.1403 (2014).
1102	54	Yang, Y., Lv, T. T., Li, S. Y. & Zhang, P. Sodium channel blockers in the management
1103		of long QT syndrome types 3 and 2: A system review and meta-analysis. J
1104		Cardiovasc Electrophysiol 32 , 3057-3067, doi:10.1111/jce.15223 (2021).
1105	55	Arbelo, E. <i>et al.</i> 2023 ESC Guidelines for the management of cardiomyopathies.
1106		<i>Eur Heart J</i> 44 , 3503-3626, doi:10.1093/eurheartj/ehad194 (2023).
1107	56	Kannankeril, P. J., Roden, D. M. & Fish, F. A. Suppression of bidirectional
1108		ventricular tachycardia and unmasking of prolonged QT interval with verapamil in
1109		Andersen's syndrome. <i>J Cardiovasc Electrophysiol</i> 15 , 119, doi:10.1046/j.1540-
1110		8167.2004.03369.x (2004).
1111	57	Miyamoto, K. et al. Efficacy and safety of flecainide for ventricular arrhythmias in
1112		patients with Andersen-Tawil syndrome with KCNJ2 mutations. <i>Heart Rhythm</i> 12 ,
1113		596-603, doi:10.1016/j.hrthm.2014.12.009 (2015).
1114	58	Pellizzon, O. A., Kalaizich, L., Ptacek, L. J., Tristani-Firouzi, M. & Gonzalez, M. D.
1115		Flecainide suppresses bidirectional ventricular tachycardia and reverses
1116		tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. <i>J Cardiovasc</i>
1117		<i>Electrophysiol</i> 19 , 95-97, doi:10.1111/j.1540-8167.2007.00910.x (2008).
1118	59	Sansone, V. & Tawil, R. Management and treatment of Andersen-Tawil syndrome
1119		(ATS). <i>Neurotherapeutics</i> 4 , 233-237, doi:10.1016/j.nurt.2007.01.005 (2007).

1120	60	Bokenkamp, R., Wilde, A. A., Schalij, M. J. & Blom, N. A. Flecainide for recurrent
1121		malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.
1122		<i>Heart Rhythm</i> 4 , 508-511, doi:10.1016/j.hrthm.2006.12.031 (2007).
1123	61	Haruna, Y. et al. Genotype-phenotype correlations of KCNJ2 mutations in Japanese
1124		patients with Andersen-Tawil syndrome. <i>Hum Mutat</i> 28 , 208,
1125		doi:10.1002/humu.9483 (2007).
1126	62	Fox, D. J. <i>et al.</i> Reduction of complex ventricular ectopy and improvement in
1127		exercise capacity with flecainide therapy in Andersen-Tawil syndrome. <i>Europace</i>
1128		10 , 1006-1008, doi:10.1093/europace/eun180 (2008).
1129	63	Barajas-Martinez, H. <i>et al.</i> Biophysical and molecular characterization of a novel
1130		de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and
1131		catecholaminergic polymorphic ventricular tachycardia mimicry. <i>Circ Cardiovasc</i>
1132		<i>Genet</i> 4 , 51-57, doi:10.1161/CIRCGENETICS.110.957696 (2011).
1133	64	Janson, C. M., Poelzing, S. & Shah, M. J. Combined inhibition of Na(+) and Ca(2)(+)
1134		channels: a novel paradigm for the treatment of incessant ventricular arrhythmias
1135		in Andersen-Tawil syndrome. <i>Heart Rhythm</i> 11 , 318-320,
1136		doi:10.1016/j.hrthm.2013.11.003 (2014).
1137	65	Bienias, P., Kostera-Pruszczyk, A., Miszczak-Knecht, M., Ciurzynski, M. & Pruszczyk,
1138		P. Propafenone is not effective for severe ventricular arrhythmias in Andersen-
1139		Tawil syndrome. Arch Med Sci 14, 248-250, doi:10.5114/aoms.2016.61010 (2018).
1140	66	Van Ert, H. A. <i>et al.</i> Flecainide treats a novel KCNJ2 mutation associated with
1141		Andersen-Tawil syndrome. <i>HeartRhythm Case Rep</i> 3 , 151-154,
1142		doi:10.1016/j.hrcr.2016.11.009 (2017).
1143	67	Fernandez, M. <i>et al.</i> Response to flecainide test in Andersen-Tawil syndrome with
1144		incessant ventricular tachycardia. <i>Pacing Clin Electrophysiol</i> 41 , 429-432,
1145		doi:10.1111/pace.13204 (2018).
1146	68	Ruijrachun, P., Junyavoraluk, A., Pithukpakorn, M., Suktitipat, B. & Winijkul, A.
1147		Successful treatment of arrhythmia with beta-blocker and flecainide combination
1148		in pregnant patients with Andersen-Tawil syndrome: A case report and literature
1149		review. Ann Noninvasive Electrocardiol 26 . e12798. doi:10.1111/anec.12798
1150		(2021).
1151	69	Ergul, Y., Ozgur, S., Onan, S. H. & Tuzcu, V. Can flecainide totally eliminate
1152		bidirectional ventricular tachycardia in pediatric patients with Andersen-Tawil
1153		syndrome? Turk Kardivol Dern Ars 46 , 718-722.
1154		doi:10 5543/tkda 2018 10 5543/tkda 2017 77856 (2018)
1155	70	Nguyen D & Ferns S I Asymptomatic ventricular tachycardia: diagnostic nitfalls
1156	, 0	of Andersen-Tawil syndrome-a case report <i>Fur Heart I Case Rep</i> 7 yty083
1157		doi:10.1093/ehicr/vtv083.(2018)
1157	71	Sato A. Takano T. Chinushi M. & Minamino T. Usefulness of the intravenous
1150	/ 1	flecainide challenge test before oral flecainide treatment in a natient with
1157		Anderson Towil syndrome, BML Case Ren 12 , doi:10.1136/bcr.2019.229628
1161		(2010)
1162	72	(2013). Maffa S. at al. Tharapautic management of ventricular arrhythmias in Anderson
1162	12	Tawil syndrome / Electrocardial 58, 37, 42, doi:10.1016/i.joloctrocard.2010.10.000
1164		(2020)
1104		

1165	73	Hayashi, H., Kawaguchi, T. & Horie, M. Effect of flecainide on T-wave alternans in
1166		Andersen-Tawil syndrome. Ann Noninvasive Electrocardiol 19 , 383-386,
1167		doi:10.1111/anec.12144 (2014).
1168	74	Junker, J. <i>et al</i> . Amiodarone and acetazolamide for the treatment of genetically
1169		confirmed severe Andersen syndrome. <i>Neurology</i> 59 , 466,
1170		doi:10.1212/wnl.59.3.466 (2002).
1171	75	Erdogan, O. et al. Oral verapamil effectively suppressed complex ventricular
1172		arrhythmias and unmasked U waves in a patient with Andersen-Tawil syndrome. J
1173		<i>Electrocardiol</i> 41 , 325-328, doi:10.1016/j.jelectrocard.2008.02.023 (2008).
1174	76	Weir, R. A., Petrie, C. J., Murday, V. & Findlay, I. N. Andersen-Tawil syndrome. Int J
1175		<i>Cardiol</i> 148 , e13-15, doi:10.1016/j.ijcard.2009.01.057 (2011).
1176	77	Delannoy, E. et al. Cardiac characteristics and long-term outcome in Andersen-
1177		Tawil syndrome patients related to KCNJ2 mutation. Europace 15, 1805-1811,
1178		doi:10.1093/europace/eut160 (2013).
1179	78	Keegan, R., Onetto, L., Gregorietti, F., Urruti, R. & Di Biase, L. Catheter ablation of
1180		frequent monomorphic ventricular arrhythmias in Andersen-Tawil syndrome: case
1181		report and focused literature review. J Interv Card Electrophysiol 66, 729-736,
1182		doi:10.1007/s10840-021-01077-w (2023).
1183	79	Abriel, H., Rougier, J. S. & Jalife, J. Ion channel macromolecular complexes in
1184		cardiomyocytes: roles in sudden cardiac death. <i>Circ Res</i> 116 , 1971-1988,
1185		doi:10.1161/CIRCRESAHA.116.305017 (2015).
1186	80	Meadows, L. S. & Isom, L. L. Sodium channels as macromolecular complexes:
1187		implications for inherited arrhythmia syndromes. Cardiovasc Res 67, 448-458,
1188		doi:10.1016/j.cardiores.2005.04.003 (2005).
1189	81	Willis, B. C., Ponce-Balbuena, D. & Jalife, J. Protein assemblies of sodium and
1190		inward rectifier potassium channels control cardiac excitability and
1191		arrhythmogenesis. Am J Physiol Heart Circ Physiol 308 , H1463-1473,
1192		doi:10.1152/ajpheart.00176.2015 (2015).
1193	82	Singer, D. H., Lazzara, R. & Hoffman, B. F. Interrelationship between automaticity
1194		and conduction in Purkinje fibers. <i>Circ Res</i> 21 , 537-558,
1195		doi:10.1161/01.res.21.4.537 (1967).
1196	83	DeMarco, K. R. & Clancy, C. E. Cardiac Na Channels: Structure to Function. <i>Curr</i>
1197		<i>Top Membr</i> 78 , 287-311, doi:10.1016/bs.ctm.2016.05.001 (2016).
1198	84	Bagal, S. K., Marron, B. E., Owen, R. M., Storer, R. I. & Swain, N. A. Voltage gated
1199		sodium channels as drug discovery targets. <i>Channels (Austin)</i> 9 , 360-366,
1200		doi:10.1080/19336950.2015.1079674 (2015).
1201	85	Noujaim, S. F. <i>et al.</i> Up-regulation of the inward rectifier K+ current (I K1) in the
1202		mouse heart accelerates and stabilizes rotors. J Physiol 578, 315-326,
1203		doi:jphysiol.2006.121475 [pii]
1204	10.111	3/jphysiol.2006.121475 (2007).
1205	86	Scheinman, M. M. Role of the His-Purkinje system in the genesis of cardiac
1206		arrhythmia. <i>Heart Rhythm</i> 6 , 1050-1058, doi:10.1016/j.hrthm.2009.03.011 (2009).
1207	87	Riera, A. R. et al. Relationship among amiodarone, new class III antiarrhythmics,
1208		miscellaneous agents and acquired long QT syndrome. Cardiol J 15, 209-219
1209		(2008).

1210	88	Follmer, C. H. & Colatsky, T. J. Block of delayed rectifier potassium current, IK, by
1211		flecainide and E-4031 in cat ventricular myocytes. <i>Circulation</i> 82 , 289-293,
1212		doi:10.1161/01.cir.82.1.289 (1990).
1213	89	Wang, D. W., Kiyosue, T., Sato, T. & Arita, M. Comparison of the effects of class I
1214		anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed
1215		rectifier K+ current of guinea-pig ventricular myocytes. <i>J Mol Cell Cardiol</i> 28 , 893-
1216		903, doi:10.1006/jmcc.1996.0084 (1996).
1217	90	Paul, A. A., Witchel, H. J. & Hancox, J. C. Inhibition of the current of heterologously
1218		expressed HERG potassium channels by flecainide and comparison with quinidine,
1219		propafenone and lignocaine. Br J Pharmacol 136 , 717-729,
1220		doi:10.1038/sj.bjp.0704784 (2002).
1221	91	Melgari, D., Zhang, Y., El Harchi, A., Dempsey, C. E. & Hancox, J. C. Molecular basis
1222		of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. J
1223		<i>Mol Cell Cardiol</i> 86 , 42-53, doi:10.1016/j.yjmcc.2015.06.021 (2015).
1224	92	Hoffmann, A., Wenk, M. & Follath, F. Exercise-induced ventricular tachycardia as a
1225		manifestation of flecainide toxicity. Int J Cardiol 11, 353-355, doi:10.1016/0167-
1226		5273(86)90040-9 (1986).
1227	93	Anastasiou-Nana, M. I. <i>et al.</i> Occurrence of exercise-induced and spontaneous
1228		wide complex tachycardia during therapy with flecainide for complex ventricular
1229		arrhythmias: a probable proarrhythmic effect. Am Heart J 113 , 1071-1077,
1230		doi:10.1016/0002-8703(87)90914-8 (1987).
1231	94	Ranger, S., Talajic, M., Lemery, R., Roy, D. & Nattel, S. Amplification of flecainide-
1232		induced ventricular conduction slowing by exercise. A potentially significant
1233		clinical consequence of use-dependent sodium channel blockade. <i>Circulation</i> 79 ,
1234		1000-1006, doi:10.1161/01.cir.79.5.1000 (1989).
1235	95	Watanabe, H. <i>et al.</i> Effects of flecainide on exercise-induced ventricular
1236		arrhythmias and recurrences in genotype-negative patients with
1237		catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm</i> 10 , 542-
1238		547, doi:10.1016/j.hrthm.2012.12.035 (2013).
1239	96	Radicke, S. et al. Effects of MiRP1 and DPP6 beta-subunits on the blockade
1240		induced by flecainide of Kv4.3/KChIP2 channels. <i>Br J Pharmacol</i> 154 , 774-786,
1241		doi:10.1038/bjp.2008.134 (2008).
1242	97	Krishnan, S. C. & Antzelevitch, C. Flecainide-induced arrhythmia in canine
1243		ventricular epicardium. Phase 2 reentry? <i>Circulation</i> 87 , 562-572,
1244		doi:10.1161/01.cir.87.2.562 (1993).
1245	98	Ikeda, N., Singh, B. N., Davis, L. D. & Hauswirth, O. Effects of flecainide on the
1246		electrophysiologic properties of isolated canine and rabbit myocardial fibers. J Am
1247		Coll Cardiol 5, 303-310, doi:10.1016/s0735-1097(85)80051-6 (1985).
1248	99	Osadchii, O. E. Flecainide-induced proarrhythmia is attributed to abnormal
1249		changes in repolarization and refractoriness in perfused guinea-pig heart. J
1250		Cardiovasc Pharmacol 60, 456-466, doi:10.1097/FJC.0b013e31826b86cf (2012).
1251	100	Osadchii, O. E. Effects of Na+ channel blockers on extrasystolic stimulation-evoked
1252		changes in ventricular conduction and repolarization. <i>J Cardiovasc Pharmacol</i> 63,
1253		240-251, doi:10.1097/FJC.000000000000041 (2014).
1254	101	Hilliard, F. A. <i>et al.</i> Flecainide inhibits arrhythmogenic Ca2+ waves by open state
1255		block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark
1256		mass. J Mol Cell Cardiol 48, 293-301, doi:10.1016/j.yjmcc.2009.10.005 (2010).

It is made available under a CC-BY-NC 4.0 International license .

1257	102	Al-Khatib, S. M. et al. 2017 AHA/ACC/HRS Guideline for Management of Patients
1258		With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A
1259		Report of the American College of Cardiology/American Heart Association Task
1260		Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation
1261		138 , e272-e391, doi:10.1161/CIR.0000000000000549 (2018).
1262	103	Bannister, M. L., MacLeod, K. T. & George, C. H. Moving in the right direction:
1263		elucidating the mechanisms of interaction between flecainide and the cardiac
1264		ryanodine receptor. <i>Br J Pharmacol</i> 179 , 2558-2563, doi:10.1111/bph.15718
1265		(2022).
1266		



Ineffective treatment

medRxiv preprint doi: https://doi.org/10.1101/2024.12.10.24316029; this version posted December 11, 2024. The copyright holder for this preprint (which was not certified by encrystation by the preprint in perpetuity.





Α

В

Input		
Response to class-lc AADs	N° of patients	References
Successful treatment	(12)	
Complete VAs suppression	9 (16.9%)	Bökenkamp; Haruna; Pellizón; Barajas; Van Ert*
>90% VAs suppression	3 (5.6%) ^{*,#,†}	Ergül; Fernandez; Nguyen [*] ; Maffè⁺; Rujirachun
Partial recovery	(33)	
>90% VAs suppression	3 (5.6%)*,#,*	Fox; Hayashi; Janson; Miyamoto; Bienias; Van Ert*
<90% VAs reducction	28 (52.8%)	Nguyen [#] ; Sato; Mazzanti; Maffè [†] ; Case 1 daughter
Ineffective treatment		
Ineffective	13 (24.5%)	Junker; Erdogan; Weir; Delannoy; Keegan; Cruz;
		Case 1; Case 2
Overall number of unique probar	1ds 53	
Non-fatal cardiac arrest (ICD shock)	(7) (13.2%)	
Reported as >90% VAs suppres	sion 1 (1.9%)	Maffè
Reported as partial recovery	3 (5.7%)	Bökenkamp; Mazzanti
Reported as ineffective	3 (5.7%)	Junker; Delannoy; Cruz

,,† same patient; VAs: Ventricular arrhythmias













16.86 nm

Solvent Accesible Surface Area (SASA; Å²)

Tabla 1. Response to class-lc antiarrhythmic drugs in the treatment of Andersen-Tawil syndrome type 1

Sex	KCNJ2 mutation	Cardiac phenotype	Tested therapy	Reported Class Ic treatment response	References
F	R218W	Polymorphic PVCs, VF	Sotalol, flecainide, propafenone Amiodarone + acetazolamide	Aborted sudden cardiac death under flecainide. Only amiodarone was effective in treating the arrhythmias.	Junker J et al. (2002)
F	R218W	PVT, TdP tachycardia, VF, prominent U waves	i.v. Flecainide 0.5mg/Kg Oral verapamil + flecainide 4 mg/kg/day ICD	One appropriate ICD shock for TdP tachycardia after 3 years of flecainide treatment Still shows frequent polymorphic PVCs, but no VT.	[.] Bökenkamp et al. (2007)
М	R218W	TdP tachycardia	Oral flecainide 4 mg/kg/day	Asymptomatic during 5 years follow-up.	
F	NR	PVCs, bigeminy, Couplets BiVT, VT	Oral flecainide	Flecainide suppressed cardiac arrhythmias.	Haruna et al. (2007)
F	R67W	BiVT	Oral flecainide 200 mg/day for 3year then switched to 300mg/day	Two BiVT recurrences and tachycardia-induced cardiomyopathy (LVEF:25%). Improvement (LVEF:55%) after increasing flecainide doses.	Pellizzón et al. (2008)
F	NR	Polymorphic PVCs, BiVT, bigeminy, NSVT, U-waves	i.v. propafenone verapamil	Propafenone was not effective in treating the arrhythmias. Verapamil revealed absence of BiVT and NSVT with frequent bigeminy episodes	Erdogan O et al. (2008)
М	V302M	BiVT, NSPVT, PVCs 24h Holter: 15671 total PVC; 1912 couplets; 358 runs of NSVT	Bisoprolol 5mg/day switched to oral flecainide 200 mg/day	Bisoprolol demonstrated no significant arrhythmia reduction. Flecainide reduced PVCs to 268; 11 couplets and no runs of VT in 24h monitoring.	Fox et al. (2008)
F	R206P	Ventricular extrasystole, BiVT, NSPVT	Nadolol switched to flecainide 2 mg/kg/day	Flecainide suppressed BiVT. Sporadic ventricular extrasystoles.	Barajas-Martinez et al. (2011)
F	R218W	Palpitation, extrasystoles	Propranolol, amiodarone, flecainide atenolol	Only atenolol improved her palpitations.	Weir et al. (2014)
serie N=6	NR	Polymorphic PVCs, NSVT, VT	β-blocker + flecainide	One of them experienced a non-fatal cardiac arrest related to PVT with NSVT under treatment.	Delannoy et al. (2014)
М	R67Q	Couplet, triplet PVCs, NSVT 24h Holter: 19389 total PVC; 2964 couplets: 91 triplets: 4 NSVT	Oral flecainide 100 mg/day + atenolol 50mg/day	Couplet, triplet PVCs, NSVT 24h Holter: 10854 total PVC; 245 couplets; 9 triplets; 1 quadrat PVCs.	Hayashi et al. (2014)
Μ	R218W H	igh-burden ventricular ectopy: 40846/da 467 VT/day	ay; Nadolol, mexiletine, flecainide amiodarone and verapamil	Neither antiarrhythmic monotherapy nor verapamil + low doses flecainide resulted in significant improvement. Verapamil + flecainide 4 mg/kg/day each resulted in decreased ectopy: 5390/day.	Janson et al. (2014)
serie N=10 (R67Q/W, R218Q/V G300V, G301T, 76in	V Couplet PVCs, BiVT, NSVT sT VA: 38407/day	Oral flecainide 100-200 mg/day	Significantly reduced the total number of VA: 11196/day.	Miyamoto K et al. (2015)
F	G146R	bigeminy, trigeminy and BiVT Pr VA: ~ 55000/day	opafenone 450 mg/day + metoprolol 50/mg/day switched to flecainide 200 mg/day	Propafenone increased Va slightly (400-800 episodes BiVT/day). Only flecainide reduced VA to ~7500/day and 5-20 short BiVT.	Bienias P et al. (2016)
F	R218L	Polymorphic PVC, bigeminy PVC PVT, BiVT	Flecainide 200 mg/day + atenolol 25 mg/day	After two ablation, proband showed transient improvement. Flecainide 100 mg/day was titrated up to 200 mg/day to suppress BiVT and PMVT, with PVCs burden decreased to <1%. She later experienced periodic paralysis.	Van Ert et al. (2016)
F	V200M	Polymorphic PVC, BiVT, NSVT PQTc, U waves	Propranolol 4mg/Kg/day+ flecainide 100 mg/m²/day	β -blocker alone was not sufficient to control PVCs. Combined with flecainide almost all PVCs disappeared. QTc interval shortened but U waves persisted.	Ergül Y et al. (2018)
F	T305I	Palpitations, high burden PVCs, bigeminy PVCs	Bisoproiol 5mg/day Flecainide 200 mg/day Acetazolamide 250 mg/day	Bisoprolol did not suppress PVCs. Bisoprolol + flecainide + acetazolamide suppressed palpitation and reduced PVC burden.	Fernández et al. (2018)
F	D71N	runs of NS BiVT, PQTc, VE 45% F	Sotalol 150mg/m²/day pafenone 300mg/m²/day + metoprolol 3mg/kg/da lecainide 4mg/kg/day + nadolol 0.75mg/kg/day	Sotalol had no effect. During first 9 months propafenone combined with ay metoprolol reduced VE to 3-6% and then progressive increased to 40%. Switched to flecainide + nadolol reduced VE to <5% in 10-month follow-up.	Nguyen D et al. (2018)
F R22	28insKSHLVEAHVR	PVCs, NSVT Dis 24h Holter: 50133 PVCs	opyramide, mexiletine, pilsicainide and verapam Atenolol (25mg) i.v. flecainide 30mg / oral flecainide 100mg	I Disopyramide, mexiletine, pilsicainide, verapamil and β-blocker failed to suppress VAs. i.v. flecainide suppressed VAs completely; oral flecainide 100mg/day reduced PVC to 13363 PVCs/day in follow-up Holter.	Sato A et al. (2019)

Tabla 1. Response to class-lc antiarrhythmic drugs in the treatment of Andersen-Tawil syndrome type 1

Age/Sex	KCNJ2 mutati	on Cardiac phenotype	Tested therapy	Reported Class Ic treatment response	References
serie N=12	NR	BiVT, bigeminy PVCs, PQTc + U-wave Holter VA: 15940 ± 17106	β-blocker + class Ic antiarrhythmics s propafenone/flecainide: 6.5±3.1 and 2.5±1.3 mg/kg/day	Flecainide and propafenone might be useful to reduce the arrhythmic burden. They were not useful in preventing life-threatening arrhythmias. Holter VA:3459±8849; two experienced cardiac arrest while on treatment.	Mazzanti et al. (2020)
F	T192I	Polymorphic PVC, bigeminy 24h Holter: 17000 VE, 900 couplets, 80 NSPVT; PQTc	Oral flecainide (200mg/day) ICD after suffering non-fatal cardiac arrest	Follow-up at 2 years showed reduction in VA to 18 isolated VE per day, Prolonged QTc and U-waves. Non-fatal cardiac arrest with VF.	Maffè et al. (2020)
F	P186R	PVT, NSPVT, Polymorphic PVCs	Elecainide 100 mg/day	Suppressed NSPVT at 5 months of follow-up.	Rujirachun P et al. (2020)
F	P186R	IBiVT, bigeminy PVCs	Metoprolol 100 mg/day	Ventricular ectopy less frequent. No VTs. Follow-up at 4 months showed U-waves and occasional ventricular ectopy.	
F	M307V	Polymorphic PVCs, PQTc, U-waves CA	Atenolol, Propranolol, Bisoprolol one or combined with Flecainide 2 mg/kg/day. + flecainide and propranolol (2-2,5mg/kg/day)	β-blocker alone failed to reduce PVC; β-blocker combined with flecainide resulted in: PVCs >14-34%, NS BiVT. After CA: high burden PVC (55%).	Keegan et al. (2023)
F	C122Y	Polymorphic PVCs, NSVT, trigeminy PQTc, U-waves Nade	Mexiletine, propafenone, lidocaine olol (120mg/day) + spironolactone (25 mg/day)	Polymorphic ventricular extrasystoles refractory to antiarrhythmic drugs (mexiletine, lidocaine, propafenone) with three appropriate ICD	Cruz et al. (2023)
F	G215D	dyspnea, fatigue, palpitations Na and dizziness with persistent ventricular bigeminy and NSPVT	adolol (20 mg/day) + flecainide (100 mg/day) switched to propafenone (225 mg/day) and mexiletine (7,7 mg/kg/day)	Increase in ventricular ectopies under Nadolol + Flecainide (18%), Nadolol + propafenone (11,2%) and Nadolol + mexiletine (13%). Currently under Nadolol (up to 13% of VE).	Case 1
F	G215D	Asymptomatic, BiVT, Na	adolol (20 mg/day) + flecainide (100 mg/day) switched to propafenone (375 mg/day) + ICD	35% VA under flecainide; 10% VA under propafenone. Currently remains clinically stable, but VAs do not disappear completely.	Case 1 - daughter
М	R67W	VE, NSVT, Nado Palpitations, PQTC, U-waves	olol (120mg/day) + Acetazolamide (250 mg/day) switched to flecainide (200mg/day). Reverted to Nadolol (80 mg/day)	Flecainide induced an asymptomatic 8-sec cardiac pause and extreme nodal bradycardia (minimum of 28 bpm). VE persist.	Case 2

Abbreviations: BiVT, bidirectional ventricular tachycardia; CA, catheter ablation; IBiVT, incessant bidirectional ventricular tachycardia; i.v., intravenous; NR, not reported; NSPVT, nonsustained polymorphic ventricular tachycardia; PQTc prolonged QTc; PVT, polymorphic ventricular tachycardia; PVCs, premature ventricular contractions; TdP, torsade de pointes; VA: ventricular arrhythmia; VE: ventricular ectopy VF, ventricular fibrillation; VT, ventricular tachycardia.